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Osteoporosis is a skeletal disease affecting 44 million Americans. A primary strategy to
prevent osteoporosis is to develop a high peak bone mass in youth. Oral Contraceptives
(OCs) alter hormones in women and could affect bone mass development. The
interaction between OCs and skeletal mineralization is poorly understood. PURPOSE:
Our aims were to 1) compare bone mineral density (BMD) of young women who had a
history of OC use with regularly menstruating controls, 2) compare changes in BMD in
controls, women who initiate OC use, and those who have a history of use, and 3) to
evaluate predictive capabilities of physical activity and years of oral contraceptives use
on changes in BMD. METHODS: We recruited women, 18 to 25 years of age, with a
history of OC use and controls. BMD at the hip, whole-body, and spine (AP,g/cm2and
width-adjusted lateral, g/cm3) was measured by dual-energy x-ray absorptiometry.
Physical activity (METs) was measured via questionnaire andgripstrength was evaluated
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slightly older than OC users. In analysis of covariance (ANCOVA), controlling for age
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of changes in BMD at any site. CONCLUSIONS: We conclude that, in the cross-
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during a time when mineral is still accruing. In the prospective analysis, regularly
menstruating controls had greater BMD accrual or less bone loss over a 12-month time
period than women with a history of oral contraceptive use.© Copyright by Hawley Chase Almstedt Shoepe
April 19, 2005
All Rights ReservedPotential Influences of Oral Contraceptive Use and Physical Activity on Bone Health:
A One-Year Prospective Study in Young Women
by
Hawley Chase Almstedt Shoepe
A DISSERTATION
submitted to
Oregon State University
in partial fulfillment of
the requirements for the
degree of
Doctor of Philosophy
Presented April 19, 2005
Commencement June, 2005Doctor of Philosophy dissertation of Hawley Chase Almstedt Shoepe presented on
April 19. 2005.
APPROVED:
Major Professor, representing Exercise and Sport Science
Chair of the Departiiht of Exercise and Sport Science
Dean of Giãduate School
I understand that my dissertation will become part of the permanent collection of Oregon
State University libraries. My signature below authorizes release of my dissertation to
any reader upon request.
Hawley Chase Almstedt Shoepe,'Author
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyACKNOWLEDGEMENTS
This research was supported by grants to Oregon State University (Principal
Investigator: Christine Snow, PhD, Student Investigator: Hawley C. Almstedt) from the
John C. Erkkila, M.D. Endowment for Health and Human Performance, Good Samaritan
Hospital Foundation, Corvallis, OR, from the Northwest Health Foundation Student
Research Award, Portland, OR, and by the OSU Bone Research Laboratory Clinical
Program.
I have many people to acknowledge. I am very grateful for the mentorship and
guidance provided by Dr. Christine Snow. Being her student has truly been a gift and I
cherish this experience. I would like to thank Dr. Mike Maksud and his generous support
of my education through the George and Rachel Maksud Fellowship. I feel honored to
represent first generation college students and receive this fellowship. Bone Research
Laboratory members (Arwen, Shantel, Kathy, Tanya, Adrienne, Karen, Jessica, Gianni,
and Jeremy) have been crucial in my education process and throughout this research
project. Thank you to Annie Shultz and Michael Bohmsen for their help in data
collection and analysis.
Most of all I want to thank my family, who has encouraged me through the
previous 11 years of college. I am confident that I never would have succeeded through
this year with out the support of my husband, Todd. He is truly my best friend and the
only person I know who will sit at the pizza parlor with me and discuss down-regulation
of the estrogen receptor and its role in explaining our results. My life undoubtedly is
better with Todd by my side.CONTRIBUTION OF AUTHORS
Dr. Christine M. Snow was involved in the overall study design, analysis of the
data, and writing of the manuscripts.TABLE OF CONTENTS
CHAPTER ONE: Potential Influences of Oral Contraceptive Use and
Physical Activity on Bone Health: A One-Year Prospective Study in
YoungWomen............................................................................. 1
Background................................................................2
Specific Aims and Hypotheses..........................................9
Methods.....................................................................12
CHAPTER TWO: Oral Contraceptive Use in Young Women is Associated
with Lower Bone Mineral Density than Controls........................................16
ABSTRACT.................................................................18
INTRODUCTION.........................................................19
METHODS..................................................................21
RESULTS...................................................................25
DISCUSSION...............................................................26
REFERENCES.............................................................32
CHAPTER THREE: Changes in Bone Mineral Density in Young Women
Using Oral Contraceptives..................................................................39
ABSTRACT.................................................................41
INTRODUCTION.........................................................42
METHODS..................................................................44
RESULTS....................................................................49
DISCUSSION...............................................................50
REFERENCES..............................................................57TABLE OF CONTENTS (Contintued)
CHAPTER FOUR: Conclusion..............................................................64
BIBLIOGRAPHY..............................................................................69
APPENDICES..................................................................................72LIST OF TABLES
Table
2.1Controls and women taking oral contraceptives (OC Users) are
similar on most variables.................................................37
2.2Current oral contraceptive doses of ethinyl estradiol (EE) and
progestogen (Prog) among women......................................37
2.3Bone mineral density (BMD, mean ± standard error and 95%
confidence intervals) of young women with a history (> .5 years)
of OC use and regularly menstruating controls........................38
3.1Reasons why participants withdrew from the study or were
removed from the analysis................................................60
3.2Controls and women taking oral contraceptives (OC Users) are
similar on most variables at baseline and 12-month follow-up......61
3.3Oral contraceptive doses of ethinyl estradiol (EE) and progestogen
(Prog) among women at visit 1 and 2...................................62
3.4Adjusted change in bone mineral density (BMD) of young women
with a history (> .5 years) of oral contraceptive use (OC users) and
regularly menstruating controls..........................................63LIST OF APPENDICES
Appendix
A. Review of Literature...............................................73
B. IRB Approval Letter and Informed Consent Document......87
C. Medical, Menstrual, Physical Activity, and Nutrition
Questionnaires......................................................93DEDICATION
This document is dedicated to my stubborn father, William Nathan Almstedt, who
was adamant that a college education was not necessary. I miss you dad and I wish you
were here to brag to your friends about your daughter, Dr. Almstedt.Potential Influences of Oral Contraceptive Use and Physical Activity on Bone Health:
A One-Year Prospective Study in Young Women
CHAPTER ONEBackground
Osteoporosis is a skeletal disease characterized by low bonemass, predisposing a
person to an increased risk of fracture. This disease is a major healthconcern affecting 44
million people in the United States, eighty percent of whoare women (National
Osteoporosis Foundation [NOF], 2002). Medical costs for osteoporosisare estimated to
total between $10 and $15 billion eachyear and the cost is expected to increase to more
than $60 billion by the year 2020 (NIH Consensus, 2001; NOF,2002). A primary
strategy to prevent osteoporosis is to develop a high peak bonemass during growth and
into young adulthood.
Bone mass accrual begins in childhood and continues increasing until itreaches a
peak between the ages of 20 and 30, dependingon bone site (Recker et al., 1992).
Specifically, Theintz et al. (1992) found peak bonemass at the femoral neck in young
women to be complete by age 16 whereas Recker and colleagues (1992) found peak
whole body bone mineral content is attained atage 29.5, while spinal peak BMD occurs
at age 28.5. The NIH consensus panel on osteoporosis (2001) states thatsomeone who
does not reach an optimal peak bone mass during childhoodor adolescence may develop
osteoporosis without experiencing accelerated bone loss. A higher peakbone mass in
childhood will help protect against age-related declines in bonemass. Some researchers
even consider osteoporosis a childhood disease manifested in adults. During growth,
reproductive health, exercise, and nutritionare all important factors that help in
developing an optimal peak bone mass.
Given the potent role of reproductive hormoneson bone development, the use of
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and third decade of life could influence development of peak bone mass. Use of
hormonal birth control is a lifestyle habit common among young women during this time.
Oral contraceptives (OCs) are currently used by 40% of American women between the
ages of 18 and 24 (Ortho-tricyclen quick facts, 2003). Oral contraceptive pills are the
most popular method of reversible contraception in the US, with more than 16 million
users. Most OC pills supplement the body with both estrogen and progesterone in order
to suppress ovulation and prevent pregnancy. Given the young age of many women
using OCs and considering that most of these women are still accruing bone,
supplemented levels of estrogen and progesterone in OCs may affect bone mineral
accrual and ultimately influence peak bone mass.
Research thus far is equivocal regarding the influence of hormonal birth controls
on bone health. Type of hormones, different dosage, method of delivery, length of birth
control use, and age at onset of use are all factors that contribute to the contradicting
nature of research to date. It is well documented that estrogen deficiency is associated
with bone loss. Studies of postrnenopausa! women and amenorrheic women have
demonstrated significant loss of bone mineral density (BMD) in the absence of estrogen
(Drinkwater et al., 1984; Johnston et al., 1985; Ohta et al., 1993; Rencken et al., 1996).
Although the mechanism between estrogen and bone is still unclear, it is evident that
estrogen has a complex interaction with bone through specific cell receptors influencing
bone metabolism. Research of hormone replacement therapy in postmenopausal women
indicates that supplemental estrogen after ovarian failure or ovariectomy decreases bone
resorption (Marcus et al., 1999).ri
The usual dosage of estrogen replacement therapy is about 1.25 mg per day of
estrogen, while the dosage of estrogen found in most combined OCs ranges between 0.20
mg to 0.35 mg per day. The type of estrogen in combined OCs is ethinyl estradiol,
however the progesterone compounds vary greatly between different prescriptions in
dosage and chemical variety. There are monophasic and triphasic OC medications
available. The monophasic prescriptions supplement the body with one dose of estrogen
and progesterone for 21 days to prevent ovulation while the triphasic type gives three
different doses of estrogen and progesterone over the course of2l days. There are also
non-oral types of birth control that contain only progesterone compounds. Two common
examples of these types of birth control are depot medroxyprogesterone acetate (DMPA)
and levonorgestrel implants. These two types of birth control slowly release
progesterone in order to prevent ovulation (Baharnondes et al., 1999; Beerthuizen et al.,
2000)
Although estrogen replacement therapy in postmenopausal women has been
shown to prevent bone loss, the effect of low-dose estrogen from OCs on bone during
normal ovarian function is poorly understood. Because of differences in endogenous
sources of hormones, comparisons of research between postmenopausal women and
premenopausal women are difficult to interpret. Few research studies have examined the
effects of different doses and types of OCs on bone and since the literature is still
controversial on this topic, there are few data that report a possible interaction between
OC, BMD and physical activity. It is unknown whether exposure to low doses of
estrogen and progesterone as in OC medications affect bone metabolism in young
Woltieli.5
It appears that previous OC use studied in perimenopausal and postmenopausal
women has a protective effect on bone (Corson, 1993; Kuohung et al., 2000). Case-
control studies of premenopausal women report a positive association between OC use
and BMD (Kanders et al., 1984; Lindsay et al., 1986). A few prospective studies of
premenopausal women have found a positive influence of OCs on bone (Recker et al.,
1992; Shargil et al., 1985), while others have not (Mazess et al., 1991).
Gambacciani, Spinetti, Cappagli et al. (1994) conducted a randomized prospective
study of OC use and calcium supplementation in 32 perimenopausal women between the
ages of 40 and 48. Perimenopausal status was defined as oligomenorrhea in the previous
3 to 6 months before entering the study. Through random assignment, half of the
participants were supplemented with 500 mg calcium while the other half were give 30
meg ethinyl estradiol plus 75 mcg gestodene. Measurements of radial BMD were
performed at baseline and every 6 months for 2 years by dual photon absorptiornetry.
Biochemical analysis included hydroxyproline, plasma bone Gla protein, serum alkaline
phosphatase, and plasma estradiol. Results showed that BMD of the radius significantly
increased by almost 2% over the course of 2 years, in the group treated with OCs. In the
group supplementing with calcium, BMD showed a significant decrease of 2% after 24
months.
Biochemical markers supported the BMD results indicating a significant increase
in bone turnover for the group taking calcium while the OC group showed a decrease in
bone turnover. Investigators concluded that administration of 30 mcg ethinyl estradiol
and 75 mg gestodene could prevent activation of bone turnover and the decrease in BMD
associated with oligomenorrhea observed in perimenopausal women.In another similar study, Gambacciani, Spinetti, Taponecoet al. (1994) reported
that low-dose OC use inhibited bone resorption in oligomenorrheic,perimenopausal
women. This study also used a prospective randomized design, however, in this
investigation, 27 age-matched eumenorrheic controlswere recruited to compare with the
treatment groups. Oligomenorrheic perimenopausalwomen in this study were randomly
assigned to groups receiving 500 mg of calciumor an OC containing 20 meg ethinyl
estradiol plus 0.15 mg desogestrel. Bone mineral density of thesecond through fourth
lumbar vertebrae was assessed using themore advanced dual-energy x-ray
absorptiometry (DXA) technology. Bone metabolism markers(hydroxyproline and
osteocalcin) and hormone levels (FSH and estradiol)were also assessed. Measurements
were performed at baseline and every 6 months for 2 years.
Hormone assay results showed that oligomenorrheicwomen not taking OCs had a
greater cycle length characterized by a significant rise in FSH levelsand a decline in
estradiol levels over the 2 year period. The rise in estradiollevels conesponded with an
increase in plasma osteocalcin and urinary excretion ofhydroxyproline, indicating
increased bone turnover. The eumenorrheic controls showedno significant changes in
hormone or bone metabolism markers. The oligomenorrheicwomen taking calcium only
showed a significant decline in BMD of 4.4% twoyears after baseline, while the
eumenorrheic controls showed no change. On thecontrary, the 27 oligornenorrheic
women who began taking OCs actually showed an increase in BMD of 2.4%at the spine
after 24 months. These results compliment the resultsof the previously discussed
investigation and indicate that OCuse in perimenopausal women may help prevent bone
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The studies of Gambacciani et al. are stronger than other research in this area due
to their randomized intervention design and because specific doses of OCs were used.
These studies were prospective in nature and women had no previous history of OC use
or HRT use. Furthermore in the work of Gambacciani et al., menstrual status was
confirmed with hormone levels and biochemical markers strengthened the BMD results.
These studies lead one to believe there may be a protective effect of OC use on bone.
These studies were conducted in perimenopausal women, which do not help answer the
question of how OC use affects attainment of peak bone mass by young women.
The literature supports a strong positive relationship between high levels of
weight-bearing activity and greater bone mass. This has been demonstrated in research
of highly weight-bearing activities, such as gymnastics. Taaffe et al. (1995, 1997) found
significantly greater BMD in college-age gymnasts when compared to controls,
swimmers, and runners. Robinson et al. (1995) found gymnasts to display greater BMD
than runners despite similar prevalence of menstrual irregularities. One would assume
that since weight-bearing exercise improves BMD and OC use may help maintain healthy
bones, the two in combination would synergistically improve BMD, however this has not
been reported.Twostudies have examined the relationship between exercise and OC use
onBMD.
Hartard et al. (1997) performed a cross-sectional analysis of BMD at the hip and
spine in 128 women between the ages of 20 and 35. Participants were divided into 4
groups depending on the years of regular physical activity and years of OC use.
Someone was placed in the high physical activity groups if she exercised more than 2
I IC 1 I 1 1 iiours per weex ior inure manyears. woineii were eaiegonzeu as iiaviiig a lung-terniexposure to OCs if they had taken oral contraceptive pills for at least 3 years. The four
groups created were; 1) high exercise and short OC, 2) high exercise and long OC, 3) low
exercise and long OC, and 4) low exercise and short OC. Group 1 displayed the highest
BMD at all sites measured, including both right and left hips and in anterior/posterior and
lateral views of the spine. When compared with group 2, the participants with short
exposure to OCs had up to 8% greater BMD at the spine and 7% greater BMD at both
right and left femoral necks. The average age of participants was 28.3 ± 3.6 years andno
significant difference in age was seen between groups.
Current literature shows that high levels of physical activity are associated with
high measurements of BMD, however this was not the case in the group of women
characterized by high exercise while taking low-dose OCs for more than 3 years. Hartard
et al. (1997) suggested that low-dose OCs might counteract the beneficial influence of
exercise on bone formation. The lack of information provided as for diet, type of OC,
and duration and type of physical activity limits conclusions from the findings. The
absence of comparisons with control participants not taking OCs limits the findings as
well. Also, many researchers in the area of exercise physiology may not consider
exercising more than 2 hours a week, very active. This does not allow for comparisons
with very athletic women who exercise many hours per week for many years.
Weaver et al. (2000) conducted a 2-year exercise intervention study with 179
women between the ages of 18 and 31. The women were randomized into control and
exercise groups. The exercisers were asked to participate in an unsupervised circuit
weight-training program three times per week, consisting of 16 upper body and 8 lower
1 1 1nfl I r 1. 1 . oouy exercises wiui iu seeoiiusUIeycnng in oeiween exercises. uxercisers were aisoasked to jump rope for a cumulative of 60 minutes per week. Results showed that the
exercise protocol did not induce significant changes in BMD compared with the control
group. However, a negative interaction between exercise and OC use was displayed by
significantly lower spine BMC and BMD measurements in the exercising participants
taking OCs. These findings could not be explained by dietary habits or calcium intake.
The results of this study were greatly limited by the poor compliance to exercise and
incomplete retention of participants. Burr et al. (2000) reported that the combination of
exercise and OC use had a suppressive effect on the normal increases in bone mass and
mechanical strength of the femoral neck in the same women.
The work cited in the previous section demonstrates that exercise and OC use
may have a complex interaction with bone that is poorly understood. To our knowledge,
these are the only studies that investigate the dual-relationship between OC and exercise
on BMD. There is limited research examining the effects of initiating OC use on BMD
especially in young healthy premenopausal women. Considering the age overlap
between skeletal consolidation and OC use, it is important to define the potential role of
OC use and exercise in modifying bone.
Specific Aims and Hypotheses
Research Question I
How does BMD of young women with a history of OC use compare to regularly
menstruating controls at baseline?10
Hypothesis 2: Since exercise has been shown to be beneficial for bone health and OC use
may be osteogenic, active women using OCs will have greater BMD than controls in this
cross-sectional analysis.
Aim 2: To test this hypothesis we will compare bone mineral density of young women
who had a history (> 0.5 years) of OC use with regularly menstruating controls.
Statistical Analysis: An ANCOVA, covarying for body mass index, will be performed to
examine between group differences in BMD.
Research Question 2
Does OC medication influence accrual of bone mineral density in young women and does
it differ in those who initiate therapy versus those with a history of OC use?
Hypothesis 2: Young women (18 and 21 years old) will demonstrate a greater rate of
bone accrual in the first 12 months after initiating OC therapy than matched controls the
same age not taking oral contraceptives. Women with a history of OC use will display
greater baseline BMD but have similar rates of bone accretion as women who have never
taken OCs.
Aim 2: To test this hypothesis, we will recruit 3 groups of women between the ages of 18
and 21. Group 1 (ii=62) will be women within the first 3 months of initiating OC use.
Group 2 (n62) women wiii have a ilisiory of continuous OC use of 1-3 years. A third11
group will serve as controls (n=62) having no history of OC use and no plans to initiate
OC use in the next 12 months. BMD will be measured by DXA of all women at the hip,
spine, and whole-body at baseline and after 12 months.
Statistical Analysis: Changes in BMD will be evaluated with an analysis of covariance
(ANCOVA) as a global test for between-group differences in rates of change in BMD
from baseline to 12 months. Participants will be divided into three groups based on OC
status (new, history, and control). Analysis will be covaried for level of exercise (MET-
hlwk) and calcium intake (mg/day).
Research Question 3
Does OC use and physical activity predict BMD accrual?
Hypothesis 3: Since exercise has been shown to be beneficial for bone health and OC use
may be osteogenic, active women using OCs will have greater gains in BMD than active
or sedentary controls. OC use and physical activity together will predict changes in
BMD values better than either independent variable alone.
Aim 3: The Aerobic Center Longitudinal Study Physical Activity Questionnaire will be
used to calculate MET-hours per week of participants. Grip strength will also be used as
an indicator of total body strength.12
StatisticalAnalysis: A multiple regression equation will be created using MET-hours per
week, grip strength, length of OC use, and calcium intake to predict changes in BMD
values.
Methods
Subjects
Young women (n= 186) between the ages of 18 and 21 will be recruited by flyers
posted on the OSU campus or by referral from physicians and nurse practitioners of
Student Health Services. Participants will be taking OCs will be limited to one of three
specific OC medications, Ortho-Cyclen, Ortho-Tricyclen, or Mircette. A website will be
created describing the study in order to ease with recruitment. Persons interested in the
study could visit the website to see if they qualify to participate and to find out more
information. Any physical contraindication that would prevent participation in the testing
protocol, a history of amenorrhea, a metabolic disease affecting bone metabolism, or a
body mass index (BMI) under 15 and over 30 would exclude subjects from the study.
The control group will have no history of OC use and will be matched to the OC group
based on age and BMI.
Measures:
At baseline, all eligible subjects will complete nutrition, physical activity, and
medical and menstrual history questionnaires (appendix A-C). Participants will undergo
height, weight, grip-strength assessments, and bone density testing.13
Bone Mineral Density
Dual-energy x-ray absorptiometry (Hologic QDR-4500A Elite, Waltham, MA)
will be used to assess BMD of the hip, spine, and whole-body. In this study, BMDofthe
spine is the primary outcome variable. All scans will be performed and analyzed by one
trained technician. The coefficient of variation for repeated DXA scans at the Oregon
State University Bone Research Laboratory are 1.5% for BMD of the whole-body and
1.0% for BMD of the hip and lumbar spine. Whole-body measurements will be used to
evaluate lean body mass and fat mass.
Anthropometric Variables
Height in cm will be measured using a Seca model stadiometer and weight will be
taken in kg using a Seca Alpha Model 770 electronic scale.
Health and Menstrual History
Subjects will initially complete a medical and menstrual history questionnaire
(appendix A) to evaluate any potential bone altering conditions or medicationuse.
Participants will be asked to answer questions regarding their menstrual history and
previous OC use.
Nutrition
Participants will complete a Block 98 Food Frequency Questionnaire (appendix
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questionnaire has previously been validated with many other diet record methods (Block
et al., 1990).
Physical Activity
Level of physical activity will be assessed using the Aerobic Center Longitudinal
Study Physical Activity Questionnaire (appendix C). This self-administered
questionnaire has previously been validated with this population (Kohl et al., 1988). The
questionnaire allows for calculation of estimated energy expenditure by multiplying
average hours per week of reported activity by the average intensity of the activity
expressed in METs. One MET represents the metabolic rate ofan individual at rest and
is set at 3.5 ml of oxygen consumed per kilogram bodymass per minute.
GripStrength
A hand held dynamometer will be used to measure grip strength in kg according
to established protocol (Heyward, 2002). Participants will perform three testson their
dominant hand, with one minute rest in between trials, the highest value will be usedin
the analysis. Grip-strength has previously been usedas an indicator of total body
strength. Some research has shown a significant relationship between grip-strengthand
BMD (Ozgocmen et al., 2000; Sinaki et al., 1989).
Sample size
Based upon expected difference in spine BMD of a medium effect size anda 2%
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identified 52 subjects needed per group. Sixty-two subjectsper group will be recruited,
since we expect no more than 20% dropoutor exclusion rate (62 subjects per group)
throughout the study.
One limitation of this design is that participants will not be randomizedinto
treatment or controls groups. Due to the many important factors in choosingan OC
medication and the importance of preventingpregnancy, a randomized design is not
practical for this population. Another weakness of this studymay be compliance with the
OC medications. If participants are not careful about taking their OC daily, ifthey switch
prescriptions mid-year, or if they go through phases of medicating andnot medicating,
this will confound results. Another potential problem is if controlsubjects depide to start
taking OC medication during the 12 month study.
To our knowledge, this will be the first study to evaluate OCuse and BMD in
young women who are still accruing bone mass. The inclusion of only low-dose OC
medications of specific prescriptions is alsoa rare quality of research in this area. The
specific research question of the relationship between physical activity andOC use on
bone is a fairly novel idea, only being examined by twogroups previously. The method
of prospectively following the participants for 12 months strengthensthe design by
allowing for evaluation of changes in BMD. Also, inclusion of thelateral spine
assessment is rare in the literature but provides a practical tool for evaluating only the
weight-bearing regions of the vertebrae, whichare of particular interest in assessing risk
of fracture.16
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Abstract
Osteoporosis is a skeletal disease affecting 44 million Americans. A primary
strategy to prevent osteoporosis is to develop a high peak bone mass in youth. Oral
Contraceptives (005) alter hormones in women and could affect bone mass development.
Fifty percent of American women between the ages of 20 and 24 use OCs. However, the
interaction between OCs and skeletal mineralization is poorly understood. PURPOSE:
Our aim was to compare bone mass (BMD) of young women who have a history of OC
use with regularly menstruating controls. METHODS: We recruited 98 women who
were 18 to 25 years of age and had a history of OC use (n=44, 3.4 ± 1.9 years of OC use)
and controls (n=58). BMD at the hip, whole-body, and spine (AP,g/cm2and width-
adjusted lateral, glcm3) was measured by dual-energy x-ray absorptiometry (DXA).
Physical activity (METs) was measured via questionnaire and grip strength was evaluated
using an isometric dynamometer. RESULTS: Groups were similar in body mass index
(BMI), fat mass, grip strength, calcium intake and physical activity but controls were
slightly older than OC users (21.3 ± 1 .9 years vs. 20.3 ± 1.6 years, p < .05). In analysis
of covariance, controlling for age and BMI, controls had significantly greater BMD than
OC users at the AP and lateral spine, femoral neck, greater trochanter, total hip, and
whole-body (p < .05). CONCLUSION: We conclude that, in this cross-sectional
analysis, oral contraceptive use by young women may compromise bone health during a
time when mineral is still accruing.
Keywords: Cross-sectional, oral contraceptives, osteoporosis, premenopausal, peak bone
mass19
Introduction
Osteoporosis is a skeletal disease characterized by low bonemass and a
consequence increase in risk of fracture. Osteoporosis affects 44 million peoplein the
United States, 80% of who arewomen [1]. Low peak bone mass is a primary risk factor
for osteoporosis and is independent of the bone lossthat occurs in adulthood [1]. Thus,
an important strategy to prevent osteoporosis is to developa high peak bone mass during
growth and into young adulthood. Bonemass accrual begins in childhood and continues
until it reaches a peak between theages of 20 and 30, depending on the bone site [2].
While peak bone mass in youngwomen is reached by about the age 16 at the hip, bone
continues to accrue at the spine and whole body through thethird decade [2, 3] During
growth, reproductive health, exercise, and nutritionare critical factors that influence peak
bone mass.
Given the potent role of reproductive hormoneson bone development, the use of
hormonal birth control medication during skeletal consolidationcould influence
development of peak bone mass. Oral contraceptive (OC)use is common among young
women. In 1995, 44% of American women between 15 and 19years and 52% between
20 and 24 years of age used the pill [4]. Most OCpills supplement the body with both
estrogen and progesterone to suppress ovulation andprevent pregnancy. OC pills
currently prescribed usually contain <35mcg of ethinyl estradiol paired with a synthetic
form of progesterone. Research to date is equivocalregarding the influence of oral
contraceptive use on bone health. Type of hormones, differentdosage, length of birth
control use, and age at onset of useare all factors that contribute to the contradicting
nature of research to date.20
It is well documented that estrogen deficiency is associated with bone loss.
Studies of postmenopausal and amenorrheic women have demonstrated significant lossof
BMD when estrogen levels are low [5-8]. Some evidence supports the supplementaluse
of estrogens during amenorrheic conditions to helppreserve bone health [9, 10] while
others do not [11, 12]. A few cross-sectional studies of postmenopausalwomen show
that previous OC use may preserve BMD [13-16] while others have shownno effect [17].
Prospective work assigning oral contraceptives to climacteric [18-21]or postmenopausal
[22, 23] women found that the estrogen supplementation from contraceptives hasa
positive influence on bone health during this stage of life. A few studies inwomen who
have not yet attained peak bone mass show that OCuse may be associated with lower
bone mass [24-26] although other investigations showno effect [27-29]. Discordant
results may be due to differences in 1) hormone dosages in oral contraceptives, 2) length
of oral contraceptive use, and 3) bone sites measured.
Given the young age of many women using oral contraceptives and considering
that many of these women are still accruing bone, supplemented levels ofestrogen and
progesterone may affect bone mineral accrual and ultimately influence peak bonemass.
Although estrogen replacement therapy in postmenopausalwomen has been shown to
prevent bone loss, the effect of exogenous low doses of estrogen (35 mcg) from oral
contraceptives on bone during normal ovarian function is poorly understood.Because of
differences in endogenous sources of hormones, comparisons of research between
postmenopausal, premenopausal, and skeletally immaturewomen are difficult to
interpret. Few research studies have examined the effects of low-dose OCson bone in
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compare bone mass of young women who had a history (0.5 years) of OC use with
regularly menstruating controls. We hypothesized that women witha history of OC use
would have greater BMD than controls.
Methods
Subjects
Young women between the ages of 18 and 25 were recruited by flyers postedon
the Oregon State University campus or by referral from practitioners of the student health
center. Women were excluded from participation if they had a history of amenorrhea,a
metabolic disease affecting bone metabolism, or a body mass index (BMJ) under 15or
over 30. The OC users were currently taking pills with 20-3 5 meg of ethinyl estradiol
and had been for> 6 months. At the time of the study subjects hadno previous
pregnancies. Women were classified as controls if they were 1) currently not using OCs
and had not used OCs in the previous 2 years or 2) had lifetimeexposure of less than 3
months.Participants had no history of using other hormonal contraception suchas
depot medroxyprogesterone acetate. Study protocol was approved by the Oregon State
University Institutional Review Board and all subjects gave written informedconsent.
A total of 58 control subjects and 44 OC users volunteered and satisfied the study
criteria. Two controls were excluded from analysis because scoliosis did not allow for
evaluation of spinal BMD in the lateral view. Another two control subjectswere
excluded because jewelry interfered with analysis of L3. Of the 98 subjects included in
this analysis (54 controls and 44 OC users) there 87 Caucasians, 4 Asians, I Afiitan22
American, 1 Hawaiian, 3 were of mixed races, and 2 declined to define theirrace. None
of the OC users smoked cigarettes however two control subjects reported smoking
between 1-5 cigarettes per day. Twenty-five (57%) of the OC users and 30 (56%) of the
controls reported drinking alcohol and none reported drinking more thanone drink per
day. Incidence of alcohol consumption did not differ between groups.
Of the 44 OC users, all were taking a prescription containing between 20 and 35
mcg dose of ethinyl estradiol (Table 2.2). An analysis comparing current dosages of
women taking an average of 35 mcg of ethinyl estradiol (n=22) and those taking an
average of 30 mcg or less of ethinyl estradiol (n=22) demonstrated no difference in BMD
between groups. Some research suggests that certain types of progestogenmay cause
greater inhibition of endogenous estrogen production [30] although limited evidence in
this area does not allow for analysis. Our group used 6 different types of progestogen at
varying doses (Table 2.2). Prescription adherence in the OC users was high with only 7
of the 44 users reporting missing 7 or less non-placebo pills in the previousyear.
Bone Mineral Density
Dual-energy x-ray absorptiometry (Hologic QDR-4500/A Elite, Waltham, MA)
was used to assess BMD (in g/cm2) of the left hip, spine, and whole body using Delphi A
software version 12.1. All scans were performed and analyzed by thesame technician.
The coefficient of variation for repeated DXA scans at the Oregon State University Bone
Research Laboratory are 1.0% for BMD of the hip and lumbar spine and 1.5% for BMD
of the whole body. The hip analysis provides data for the trochanter, femora! neck, and
total hip regions. The spine scans allow for analysis ofL!.4in the anterior-posterior (AP)23
andL24in the lateral view. Because of the popularity of belly button piercings in this
population and its interference with analysis of the fourth vertebra, results of the third
lumbar vertebrae (L3) will be used in this evaluation. A separate analysis comparing
BMD of all four vertebrae in the AP spine scan with BMD ofL3when excluding
participants with belly button ring interference, revealed no statistical differences.
Therefore, in order to maximize subject number, analysis of only theL3vertebra is
reported. Whole body measurements were used to evaluate total BMD, lean body mass,
and fat mass.
Physical Activity and Strength
Regular physical activity was assessed using the Aerobic Center Longitudinal
Study Physical Activity Questionnaire [31]. The questionnaire allows for calculation of
MET-hours per week by multiplying average hours per week of reported regular physical
activity by the average intensity of the activity expressed in METs (metabolic
equivalents). One MET is equal to 3.5 mL of oxygen consumption per kg-mm. This
self-administered questionnaire has previously been validated with this population [32].
A hand-held dynarnometer (Stoelting Co., Chicago, 11) was used to measure grip strength
in kg according to an established protocol [33]. Grip strength has previously been used as
an indicator of total body strength and some research has shown a significant relationship
between grip strength and BMD [34]. Participants performed three grip strength testson
their right hand, with one minute rest in between trials; the highest valuewas used in the
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Other Measures
Height in cm was measured using a Seca model stadiometerand weight was taken
in kg using a Seca Alpha Model 770 electronic scale.Body mass index (BMI)was
calculated by dividing weight in kg by thesquare of height in meters. Subjects
completed a medical and menstrual history questionnaireto evaluate health status and
any previous use of hormonal contraception. Questionnaires includedage of menarche,
cycle regularity, previous pregnancies, lactating habits,and potential bone altering health
conditions or medications. OCusers identified the type of medication used and duration
of use for each prescription if necessary along with descriptionsof any lapse in use.
Number of fractures, smoking habits, and alcohol consumptionwere also recorded. The
Block 98 Food Frequency Questionnairewas used to evaluate dietary and supplemental
intake of calcium and vitamin D {35].
Statistics
Pearson correlations were run to evaluate relationshipsbetween independent
variables and BMD. To evaluategroup differences in BMD between OC users and
regularly menstruating controlswe performed a two-tailed analysis of covariance
(ANCOVA). Pearson correlation coefficients revealedthat BMJ was significantly related
to BMD at all sites measured (r=0.31-0.56). Since BMI explainsup to 20% of the
variation in BMD of women [36]we covaried for it in our analysis. Age was alsoa
covariate since OC users were slightly, but significantly older(0.9 years) than controls25
(Table 2.1). All statistics were analyzed using theSPSS software version 11.0 (Chicago,
Ii). We chose an alpha level equalto or less than 0.05 to be considered statistically
significant.
Results
Groups were similar in height, weight, BMI, fatmass, physical activity, grip
strength, lean mass, percent body fat, calcium intake,vitamin D intake, and age at
menarche (Table 2.1). However, despite limiting inclusioncriteria to women between
the ages of 18 and 25, OC userswere almost 1 year older than controls (Table 2.1).
Calcium and vitamin D intake included dietary andsupplemental sources of these
nutrients. The average length of oral contraceptiveuse was 3.4 years (± 1.9) with a range
of 0.52 to 8.21 years.
In analysis of covariance, controlling forage and BMI, controls had significantly
greater BMD than OC users atL3in the AP and lateral spine (p<.Ol, Table 2.3). The
ANCOVA revealed significant differences in BMDat the femoral neck, greater
trochanter, total hip, and whole body (p<.Ol). Controlsdemonstrated the largest
advantage at the spine, displaying 1.0% and 2.6%greater BMD atL3in the lateral and
AP views, respectively. Percentmean differences at the femur and whole body ranged
from 0.8% to 1.8% in favor of the control subjects.However, there was an overlap
between groups in the 95% confidence intervalsat all sites except the AP spine. This is
reflected by the negative va1ueson the lower end of the confidence intervals of the
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Discussion
We report that young women witha history of oral contraceptive use have lower
BMD than controls. Specifically, controls had 1.0-2.6%greater BMD at the spine, 0.8-
1.8% greater BMD at the hip, and 1.1% greater BMD of thewhole body compared to oral
contraceptive users. These results do not supportour hypothesis, as we expected a
history of exposure to exogenous estrogen from oralcontraceptives to cause an increase
in bone mineral density.
This study has several strengths. Our subjectswere all young women within the
narrow age range of 18 to 25 years. To our knowledge, the current study is thefirst
cross-sectional evaluation OC use and BMD in thisage group of women. Seventy-five
percent of our participants started using oral contraceptives before theage of 18 years,
with 34% (n= 15) starting before theage of 16 and 41% (n=3 3) starting after age 16years
and before age 18 years. In contrast to other cross-sectionalresearch, in this area, our
women were a homogeneous group who were developmentally similar withrespect to
skeletal age. Thus, we were able to evaluate differencesin bone between current OC
users with a history of use during growth and skeletal development with thosewho had
not taken OCs during adolescence. According to the literature[3], our subjects had
reached peak bone mass at the hip (16 years). However,since some of the users (n 15)
began using hormonal contraception prior to this time,we speculate that the supplemental
hormones could have altered bone metabolism, thus reducingbone mass accrual at the
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between 20-35 mcg of ethinyl estradiol. Data fromthe Oregon State University Student
Health Services Pharmacy (personal communication,2003) reveal that 99% of oral
contraceptives prescribed in 2003 contained 20-35mcg doses of ethinyl estradiol. We
believe the doses taken by our subjects reflectcurrent norms in the U.S. for thisage
group, and thus are representative of the general population ofyoung women taking oral
contraceptives. The specification of estrogen dose inthe OC medications israre of
cross-sectional research in this area. Also,we assessed BMD of the lateral spine.
Scanning in the lateral projection allows isolation ofthe primarily trabecular bone of the
vertebral body that is highly sensitive to changesin hormone levels.
This study also had several limitations. Cross-sectionalresearch does not allow
for conclusions regardingcause and effect. Our OC users were slightly older than
controls and could have affected results. To reducethis bias, we covaried forage in our
analysis. Subjects in this study self-selectedto OC use and perhaps there are inherent
differences in bone betweenyoung women who choose to use hormonal contraception
and those who do not. However, inour analysis of potential confounders (e.g. physical
activity, strength, dietary intake, smoking habits,alcohol consumption, menstrual, and
contraceptive history) we foundno differences between groups. Also, allwomen in this
study were college students and thus had similareducational backgrounds. Lastly,
because of the overlapping of confidence intervalsbetween groups at most bone sites,
there is not absolute certainty that the controlshad higher BMD than OCusers.
Longitudinal research will help definea potential cause and effect relationship. Whether
this overlap is due to genetics, lifestyle,or both is unclear.28
Our results support reports from longitudinal work. Conclusionsof a non-
randomized intervention of an oral contraceptive containing20 mcg ethinyl estradiol,
compliment those of ours. Polatti et al. [26] followed BMDand turnover markers
prospectively in 200 women between theages of 19 and 23. After 5 years of follow-up,
controls (n=7l) had a significant increase of nearly8% spinal BMD while OC users
(n=74) demonstrated no change. Both theage and year of starting oral contraceptives of
participants in this study are similar to that ofour subjects. Burr et al. [25] and Weaver et
al. [24] examined young (ages 18-31)women with a history of OC use and controls who
initiated a weight-bearing exercise intervention. Comparedto controls, after 24 months
of exercise, OC users demonstratedno change in spine bone mineral content while the
exercising non-users increased by about 2% [24]. Womenwho neither exercised nor
took OCs had the greatest improvements in femoralneck BMD although changes at 24
months were not significantly different than exercisingor non-exercising OC users [25].
Results of these analyses may have been impacted bya high drop out rate. The
investigatiohs began with 179 [24] and 123 [25]women, however after 24 months sample
sizes of 55 [24] and 46 [25] remained for analysis.Weaver et al. [24] suggested that
perhaps newly-formed bone in the OCusers was not well mineralized due to a sub-
optimal calcium intake. Our groups did not significantlydiffer in calcium or vitamin D
intakes (Table 2.1) and theiraverage calcium intake was above national levels for their
age group according to NHANES III data [37]. Inour study, a greater percent of controls
were consuming levels of calcium and vitamin D below recommendedamounts. Of the
controls, 59% and 50% were below adequate intakelevels for calcium and vitamin D
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BMD despite the poor nutrient intakes, suggesting thatour results were not due to sub-
optimal nutrient intakes but ratherexposure to OCs. It is unlikely that a diet low in
vitamin D could affect our results considering datacollection for this study took place in
the fall after ample exposure to sunlight duringthe summer months.
Other prospective research in thisarea contradicts our findings. Lloyd et al. [27]
followed adolescent girls for 8years measuring their whole body bone mass (BMC) and
bone mineral density annually between theages of 12 and 20 years. Girls who began
using oral contraceptives in that time period (n=28)had whole body BMC and BMD that
was similar to non-users (n=34). Subjects were taking OCs containing50 mcg or less of
ethinyl estradiol and theaverage duration of use was 22 months. Oral contraceptive
users in this analysis were slightly older (4 months) than controls, howeverLloyd et al.
[27] did not control for age nor BMI whichmay also significantly alter findings. Reed et
al. [38] also reported no differences in BMD betweenOC users and controls in an
observational prospective study. The self-selected OCusers (n=64) and controls
(n=114), between the ages of 18 and 39years, showed no significant differences at
baseline or in changes of BMDover time at the hip, spine, or whole body. However,
when examining the 18 to 21year old women separately, Reed et al. [38] reported that
OC users had a nonsignificant trend for smaller changesin BMD at all sites after 24 and
36 months when compared with similarly agednon-users.
Our results support the work ofa multi-center trial of over 500 women between
the ages of 25 and 45years, conducted by Prior et al. [39]. They reported that BMD of
the hip and spine was lower in premenopausalwomen who used OCs for3 months in
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who had never used OCs had 3.6%, 5.5%, and 4.6%greater BMD than current OC users
at the femoral neck, trochanter, and AP spine, respectively.Although the magnitude of
differences in BMD in ourgroup was less than that of Prior et al. [39], reasons including
shorter length of OC use, smaller sample size, andmore homogeneity in our population
may in part explain those differences.
Some investigations report no differences in bone,mass between OC users and
controls [40, 41]. Garnero et al. [41] reportedno differences in BMD of the hip, spine or
whole body between 52 premenopausal OCusers and 156 controls (ages 3 5-49 years).
However, Garnero et al. [41] did detect significant differencesin bone markers indicating
that women taking OCs with 30meg of ethinyl estradiol had lower resorption and
formation markers than controls. Unlikeour OC users, those of Gamero et al. [41] were
older (39.3 years) and started taking oral contraceptivesin young adulthood (average
history = 6.7 years). Thus it is possible that the influenceof OCs on bone is not relevant
after skeletal consolidation. Lloyd et al. [40] foundthat trabecular bone density of the
lumbar spine, measured by quantitative computed tomography,was similar in between 11
OC users and 14 controls early in the fourth decade oflife. Researchers did not report
physical activity or nutrient intakes that could significantlyalter results.Results of
Lloyd et al. [40] may be contradicting toours because 1) they employed different
techniques for measuring BMD thanus, 2) their OC users were taking 50 mcg mestranol
while ours were taking 20-35meg ethinyl estradiol, and 3) their women were older (3 1-
33 vs. 21) and started taking OCs ata later age (26 vs. 18) than our subjects.
One cross-sectional study reportsa positive association between exposure to OCs
P¼4r'\...c+i .,1fAll r' ni,cr :.. I 4.)J L LII. AAIY%..)LL5UL¼U '.JL' t4)UUU L)IYILI III/ t J WUJII(A131
between the ages of 20 and 69years. In a separate analysis of premenopausalwomen,
spine BMD was 3.3% higher in those who had beenexposed to OCs; howeverno
differences were detected at the hipor whole body. The average age at first exposure to
OCs was 21.1 ± 5.7 years which hadno detectable effect on current BMD. Investigators
did not specify the dose of OC medications beingused by their participants.
Several studies have showna decrease in bone formation and resorption markers
in premenopausal women whouse oral contraceptives. Specifically osteocalcin, alkaline
phosphatase, hydroxyproline, and deoxypyridinolineare lower in OC users suggesting an
overall slowing of bone turnover [24, 25, 29, 41,43]. In pen- or postmenopausalwomen
a slowing of bone metabolism could help preserve bonemass in comparisons to their
peers. However, in young women who are still experiencing skeletalconsolidation, a
reduction in bone turnover could impede bone accrual.In our study, perhaps OCusers
experienced reduced bone turnover whilenon-users had normal turnover explaining the
differences reported here. Even thoughwe detected small differences between groups in
BMD (0.8%- 2.6%), research of antiresorption therapies in postmenopausal women
suggest that a I % increase in BMD of the hipor spine results in a 10% or 7% reduction
in fracture risk, respectively [44]. Controls inour study had 2.6% greaterL3AP BMD.
If this deficit continues into adulthood, OCusers may be at an 18% greater vertebral
fracture risk than controls.
Our findings suggest that the use of oral contraceptivesduring late adolescence
may alter bone metabolism and thus reduce peak bonemass in young women. We report
that controls between theages of 18 and 25 have 1 .0-2.6% greater BMD at the spine, 0.8-
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users of the same age. Our results indicate that oral contraceptive use during adolescence
and early adulthood may be associated with lower bone mineral densityand may
compromise peak bone mass.
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Table 2.1
Controls and women taking oral contraceptives (OC Users)are similar on most variables.
However, OC users are slightly older than controls and havebeen taking oral
contraceptives an average of 3.4 years.
Variables OC Users (n=44) Controls (n=54
Age(yrs)* 21.3±1.9 20.4± 1.6
Height (cm) 167.2+6.1 166.5-f6.4
Weight (kg) 64.8+10.6 63.1+9.3
BMJ(kg/rn2) 23.1±3.4 22.7±2.9
Physical Activity (METs) 52.3±41.1 60.2±47.1
Grip Strength (kg) 31.4±4.8 32.2 ±4.2
Lean Mass (kg) 45.0±7.4 45.8±5.7
Percent Body Fat 26.9±5.6 26.5±4.3
Calcium Intake (mg/d) 1053±503 1006±501
VitaminD Intake 338 ±230 258± 198
Age at Menarche 12.9+1.3 12.7+1.6
History of OC Use (yrs)* 3.4±1.9 0
Mean ± Standard Deviation
* Significantly different betweengroups (p<.Ol)
Table 2.2
Current oral contraceptive doses of ethinyl estradiol (EE)and progestogen (Prog) among
women
N Dose EE (mcg) Prog Dose (mg) Type of Prog
2 20 0.15 desogestrel
1 20 1.0 norethindrone
4 20 0.1 levonorgestrel
3 25 0.18/0.215/0.25 norgestimate
3 30 0.15 desogestrel
1 30 0.15 levonorgestrel
2 30 30 desopirenone
1 30 1.0 norethindrone
1 30 0.3 norgestrel
4 30/40/30 0.05/0.075/0.125 levonorgestrel
1 35 1.0 norethindrone
14 35 0.18/0.215/0.25 norgestimate
6 35 0.25 norgestimate
1 35 0.4 norethindrone38
Table 2.3
Bone mineral density (BMD, mean± standard error and 95% confidence intervals) of
young women with a history (> .5 years) of OC use and regularly menstruating controls.
By analysis of covariance (covariates = age, BMI), controls hadgreater BMD at all sites
(p <0.01). The confidence interval of the difference is the control group's confidence
interval minus the mean BMD of the OCusers.
Bone Site (glcm2) OC Users OC Users Controls Controls CI of the
(n44) 95% CI (n=54) 95% CI Difference
L3APBMD* 1.090±0.02 1.059-1.1211.119±0.011.091-1.1470.001-0.057
L3Lateral BMD* 0.854 ± 0.01 0.826 - 0.8810.863 ± 0.010.8380.888-0.0 16 0.034
Femoral Neck BMD* 0.9 13 ± 0.02 0.878 - 0.9470.923 ± 0.020.892 - 0.955-0.0210.042
Trochanter BMD* 0.787 ± 0.02 0.756 -0.8 180.793 + 0.010.765 - 0.821-0.022 - 0.034
TotalHipBMD* 1.028±0.020.994- 1.0621.047±0.021.017- 1.078-0.011 0.050
WholeBodyBMD* 1.135±0.01 1.112-1.1591.147±0.011.126-1.168-0.009-0.033
*Controls greater than OC users (p<.Ol)
AP=anterior posterior
Clconfidence intervalsw
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Abstract
Osteoporosis is a skeletal disease affecting 44 million Americans. A primary
strategy to prevent osteoporosis is to develop a high peak bone mass in youth. Oral
contraceptives (OCs) alter endogenous hormone production inwomen and could affect
bone mass development. Fifty percent of Americanwomen between the ages of 20 and
24 use OCs. However, the interaction between OCs and skeletal consolidation is poorly
understood. PURPOSE: Our aim was to compare 12-month changes in bone mineral
density (BMD) of young women currently taking oral contraceptives for> 0.5years to
young women who were regularly menstruating controls. METHODS: We recruited 69
women who were 18 to 25 years of age who had a history of OC use (n=39, 3.3 ± 1.8
years of OC use at baseline) or served as controls (n=30). BMD of the hip, whole body,
and spine [volumetric (g/cm3), lateral, and AP (g/cm2)] was measured by dual-energyx-
ray absorptiometry (DXA). Physical activity (METs) was measured via questionnaire
and grip strength was evaluated using an isometric dynamometer. RESULTS: Groups
were similar in weight, percent body fat, grip strength, calcium intake and physical
activity at baseline and follow-up. However at baseline, OCusers were slightly older
than controls (20.3 ± 1.8 yrs vs. 21.3 ± 1.8 yrs,p <.05). Over 12 months, OC users lost
significantly more weight than controls (-0.8 ± 3.8 kg vs. 1.0± 3.1 kg), which was
specifically due to loss of lean mass (-1.0 ± 1.7 kg vs. -0.1± 1.4 kg). By analysis of
covariance (covariates = age at baseline, change in weight), oral contraceptiveusers had
greater bone loss at L3 in the lateral view than controls whereas, controls had greater
increases inL3volumetric BMD, and in BMD at the total hip, and whole body than OC
users (p < 0.05). No significant differences were detected at theL3in the AP view.42
CONCLUSION: We conclude that, in this prospective analysis, regularly menstruating
controls had greater BMD accrual or less bone loss over a 12-month time period than
women with a history of oral contraceptive.
Keywords: Oral contraceptives, osteoporosis, premenopausal, peak bone mass,
prospective
Introduction
Osteoporosis is a skeletal disease characterized by low bone mass anda
consequence increase in risk of fracture. Osteoporosis affects 44 million people in the
United States, 80% of who are women [1]. Low peak bone mass is a primary risk factor
for osteoporosis and is independent of the bone loss that occurs in adulthood [1]. Thus,
an important strategy to prevent osteoporosis is to develop a high peak bone mass during
growth and in young adulthood. Bone mass accrual begins in childhood and continues
until it reaches a peak between the ages of 20 and 30, depending on the bone site [2].
While peak bone mass in young women is reached by about the age 16 at the hip, bone
continues to accrue at the spine and whole body through the third decade [2, 3] During
growth, reproductive health, exercise, and nutrition are critical factors that influence peak
bone mass.
Given the potent role of reproductive hormones on bone development, theuse of
hormonal birth control medication during skeletal consolidation could influence
development of peak bone mass. Oral contraceptive (OC) use iscommon among young
women. in 1995, 44% of American women between 15 and 19 yeaisand52% between43
20 and 24 years of age have used oralcontraceptives [4]. Most OC pills supplementthe
body with both estrogen andprogesterone to suppress ovulation and preventpregnancy.
OC pills currently prescribed usually containf 35 mcg of ethinyl estradiol paired with a
synthetic form of progesterone. Researchto date is equivocal regarding the influence of
oral contraceptive useon bone health. Type of hormones, different dosage, lengthof use,
and age at onset of useare all factors that contribute to the contradictingnature of
research to date.
The few studies examining oral contraceptiveuse in women who have not yet
attained peak bone mass, show that OCuse may be associated with lower bonemass[5-
7] although other investigations showno effect [8-1 1]. Discordant results are likely due
to differences in length of oral contraceptiveuse, age at which oral contraceptive usewas
initiated, dosage of prescription, and bonesites measured.
Given the young age ofmany women using oral contraceptives and considering
that many of thesewomen are still accruing bone, supplemented levels ofestrogen and
progesterone may affect bone mineral accrual andultimately influence peak bonemass.
Although estrogen replacement therapyin postmenopausal women has been shownto
prevent bone loss, the effect ofexogenous low doses of estrogen (35mcg) from oral
contraceptives on bone accrual is poorly understood.Because of differences in
endogenous sources of hormones, comparisonsof research between postmenopausal,
premenopausal, and skeletally immaturewomen are difficult to interpret. Few research
studies have examined the effects of low-doseOCs on bone in youngwomen who are
still accruing bonemass. In the current study we posed the question; doesOC medication
1 iiUj miuiw UC111LY iiiyoung wwiiein10 iiivesugaie tiiis query,44
we compared changes in bone mineral density over a 12-month period between young
women who had a history (>0.5 years) of OC use and regularly menstruating controls.
We hypothesized that due to the additional estrogen exposurewomen with a history of
OC use would have greater gains in BMD over a 12 month time period than controls.
Methods
Subjects
Young women between the ages of 18 and 25 were recruited to participate ina 12
month prospective evaluation of bone mineral density. Subjects completed testing and
BMD scans when entering the study and 12 months later. Women who volunteeredfor
the study were informed of the longitudinal nature, and asked to maintain theirstatus as
either an oral contraceptive user or as a control. Women excluded from participationif
they had a history of amenorrhea in the last 5years, a metabolic disease affecting bone
metabolism, or a body mass index (BMI) under 15or over 30. At baseline, the OC users
were currently taking pills with 20-3 5 mcg of ethinyl estradiol and had been for> 6
months. All subjects had no previous pregnancies. Womenwere qualified as controls if
they were 1) currently not using OCs and had not used OCs in the previous2 years or 2)
had a lifetime exposure of less than 3 months.Participants had no history of using other
hormonal contraception, such as depot medroxyprogesterone acetate, in thelast 5 years.
Five of the OC users and4of the controls reported some menstrual irregularities in the
past, experiencing between4and 9 menstrual cycles per year. Reasons for initiating oral
contraceptive use include; contraception, aene tieainieni, reduce eranipilig, conirolbleeding, prevent migraines, and desire for predictable cycles. The Oregon State
University Institutional Review Board approved the study protocol and all subjectsgave
written informed consent.
A total of 40 control subjects and 45 OC users volunteered and satisfied the study
criteria at baseline. Table 3.1 states the reasons why participants withdrew from the
study or were excluded from analysis. Of the 69 subjects included in this analysis (30
controls and 39 OC users) there were 60 Caucasians, 3 Asians, 1 Hawaiian, 3were of
mixed races, and 2 declined to define theirrace. None of the participants smoked
cigarettes and the incidence of alcohol consumption did not differ betweengroups.
Twenty-one (70%) of the OC users and 26 (66%) of the controls reported drinking
alcohol and none reported drinking more thanone drink per day. Three OC users and 6
controls reported drinking alcohol less often at follow-up compared to their first labvisit,
while 3 OC users and 4 controls reported drinkingmore at follow-up than at the time of
their first lab visit.
The average length of oral contraceptive use at baselinewas 3.3 years (± 1.8) with
a range of 0.5 to 8.0 years. Of the 39 OC users, all were taking a prescription containing
between 20 and 35 meg dose of ethinyl estradiol (Table 3.3). Some researchsuggests
that certain types of progestogen may cause greater inhibition of endogenousestrogen
production [12] and may affect bone health [13] although limited evidence in thisarea
does not allow for analysis. Our group used 6 different types ofprogestogen at varying
doses (Table 3.3). Eleven subjects changed their oral contraceptive prescriptionin the 12
months between their first and second lab visit, however ethinyl estradiol dosage(20-3 5
mcg) was maintained. Prescription adherence in the OCusers was high with only 6 of46
the 39 users reporting missing more than 7 non-placebo pills in the previousyear.
Average number of pills missed in the 12-month study period was 3.5 pills.
Bone Mineral Density
Dual-energy x-ray absorptiometry (Hologic QDR-45 00/A Elite, Waltham, MA)
was used to assess BMD, ing/cm2of the left hip, anterior-posterior (AP) spine, and
whole body and in g/cm3 of the third lumbar vertebrae at baseline and 12 months later.
All scans were performed and analyzed by the same technician using Delphi A software
version 12.1. Change in bone mineral density was calculated for each participant by
subtracting the BMD of her 12-month visit from baseline results. The coefficient of
variation for repeated DXA scans at the Oregon State University Bone Research
Laboratory are 1.0% for BMD of the hip and lumbar spine and 1.5% for BMD of the
whole body. The spine scans allow for analysis ofL14in the AP view andL24in the
lateral view. Because of the popularity of belly button piercings in this population and its
common interference with analysis of the fourth lumbar vertebra, results of only the third
lumbar vertebrae (L3) will be used in this evaluation. A separate analysis comparing
BMD of all four vertebrae in the AP spine scan with BMD of L3 when excluding
participants with belly button ring interference, revealed no statistical differences.
Therefore, in order to maximize subject number, analysis of only the L3 vertebra is
reported. Whole body measurements were also used to evaluate total BMD, lean body
mass, and percent body fat.47
Physical Activity and Strength
Regular physical activity was assessed using the Aerobic Center Longitudinal
Study Physical Activity Questionnaire at baseline and 12-months [14]. The questionnaire
allows for calculation of MET-hours per week by multiplying average hours per week of
reported regular physical activity by the average intensity of the activity expressed in
METs (metabolic equivalents). One MET is equal to 3.5 mL of oxygen consumption per
kg-mm. This self-administered questionnaire has previously been validated with this
population [15]. A hand-held dynamometer (Stoelting Co., Chicago, Ii) was used to
measure grip strength in kg according to an established protocol at baseline and 12-
months [16]. Grip strength has previously been used as an indicator of total body strength
and some research has shown a significant relationship between grip strength and BMD
[17]. Participants performed three grip strength tests on their right hand, with one minute
of rest in between trials; the highest value was used in the analysis.
Other Measures
Height in cm was measured using a Seca model stadiometer and weight was taken
in kg using a Seca Alpha Model 770 electronic scale at both visits. At baseline subjects
completed a medical and menstrual history questionnaire to evaluate health status and
any previous use of honnonaI contraception. Information provided included age of
menarche, cycle regularity, previous pregnancies, and potential bone altering health
conditions or medications. OC users identified the type of medication used and duration
of use for each prescription, if necessary, along with descriptions of any lapse in use. Inbetween lab visits, subjects reported to researchers every 3 months any change in use of
their oral contraceptive medication and any if any pills were missed. Musculo-skeletal
injuries, smoking habits, and alcohol consumption were also recorded at each visit. The
Block 98 Food Frequency Questionnaire was used to evaluate dietary and supplemental
intake of calcium and vitamin D at baseline and follow-up [18]. Calcium and vitamin D
intake reported here includes dietary and supplemental sources of those nutrients.
Statistics
Pearson correlations were run to evaluate relationships between independent
variables and change in BMD. Results revealed that change in body weight was
significantly related to changes in total hip and whole body BMD (r=O.34 and r=.23,
p<O.O5 respectively). To evaluate between group differences in change of BMD over 12
months, we performed a two-tailed analysis of covariance (ANCOVA) and covaried for
initial age and change in weight. We covaried for change in weight because 1) change in
weight from baseline to follow-up was significantly different between groups, 2) change
in weight was correlated to changes in hip and whole body BMD, and 3) changes in soft
tissue surrounding bone due to weight loss could introduce measurement error of BMD
via DXA [19]. We also covaried for age since OC users were slightly, but significantly
older (1.0 years) than controls (Table 3.1). All statistics were analyzed using the SPSS
software version 11 .0 (Chicago, II). We chose an alpha level equal to or less than 0.05 as
statistically significant.Results
Groups were similar in height, weight, lean mass, physical activity, grip strength,
percent body fat, calcium intake, vitamin D intake, and years of menstruation at both
visits (Table 3.2). However, despite limiting inclusion criteriato women between the
ages of 18 and 25, OC users were almost 1 year older than controls at both time points
(Table 3.1). Changes in weight and leanmass between over 12 months were significantly
different between groups. The oral contraceptiveusers in this study lost weight and lean
mass, while controls gained weight (Table 3.2). Specifically, the OC users lost
significantly more lean mass compared to controls -1.0± 1.7 kg vs. -0.1 ± 1.4 kg
respectively, thereby explaining the difference in weight loss betweengroups.
In analysis of covariance, controlling for age and change in weight, OCusers lost
significantly more BMD than controls atL3in the lateral view of the spine (Table 3.4).
Controls had significantly greater gains in L3 volumetric BMD (g/crn3) andBMD(g/cm2)
of the total hip and whole body than OCusers. The change in BMD at L3 in the AP view
was not different between groups. OC users demonstrated the largest disadvantage of
BMD in the lateral view of the spine, displayinga loss of 3% of their baseline BMD
values, while controls lost only 0.5%. Discrepancieswere also large in volumetric BMD
of the spine, where controls gained 1.2 % of baseline BMD while OCusers lost 0.8%.
Percent increases in BMD of the total hip (0.8%vs. 0.6% for controls and OC users,
respectively) and whole body (0.3% and 0% for controls and OCusers, respectively)
although significantly different were quite small and not meaningful.50
Discussion
We report that young women witha history of oral contraceptive use have
significantly different changes in BMDover 12 months than controls and this difference
is most pronounced in the vertebral bodies.Specifically, OC users lost 3.0% of lateral
spine BMD while controls lost 0.5% BMD,OC users lost 0.8% while controls gained
1.2% volumetric BMD ofL3.No differences in change of BMDwere detected at the
spine in the anterior-posterior view. Theseresults do not support our hypothesis,as we
expected a history of exposure toexogenous estrogen from oral contraceptives to result in
greater increases in bone mineral density.
This study has several strengths. At baseline,our subjects were all within the
narrow age range of 18 to 25 years at baseline. Sixty-sixpercent (n=26) of the OC users
started taking oral contraceptives ator before the age of 18 years, with 28% (n= 11)
starting before the age of 16 and 38% (n=1 5)starting after age 16 years and beforeage 18
years. According to the literature [3], our subjects had reached peakbone mass at the hip
(16 years). However, sincesome of the users (n=1 1) began using hormonal
contraception prior to this time,we speculate that the supplemental hormones could have
altered bone metabolism, thus reducing bonemass accrual at the hip before entering our
study and at the spine during this 12 monthinvestigation. Since the literaturesupports
attainment of peak bone mass at the spine andwhole body late in the third decade of life
[3], our subjects at theaverage age of2l .8 (at follow-up) have not yet reached peakbone
mass at these sites and therefore their current oral contraceptiveuse could affect skeletal
consolidation at the spine andwholebody. Women in this studywere all taking low-dose51
oral contraceptives containing between 20-35meg of ethinyl estradiol. Data from the
Oregon State University Student Health Services Pharmacy(personal communication,
2003) reveal that 99% of oral contraceptives prescribed in 2003contained 20-35 mcg
doses of ethinyl estradiol. We believe the doses used byour subjects reflect current
norms in the U.S. for this age group, and thus our results are generalizableto young
American women on oral contraceptives.Controlling for the estrogen dose in the OC
medications is rare of research in thisarea. Another strength is that we assessed BMD of
both the AP and lateral spine. Scanning in the lateralprojection allows for isolation of
the primarily trabecular bone of the vertebral body thatis highly sensitive to changes in
hormone levels. We detected no differences in change inBMD of the spine in the
anterior-posterior view, which includes bone content of thespinous process. Since we
found significance between groups in the lateral andnot the AP view, exogenous sources
of hormones from oral contraceptivesappear to affect the trabecular bone of the vertebrae
and have less of an influence on the primarily cortical boneof the posterior elements.
Additionally, scanning in both the AP and lateral projectionsallowed for evaluation of
volumetric BMD (g/cm3), which is rare in published literatureto date. Estimating
volumetric BMD using the width-adjusted values providesthree-dimensional
measurement of volume not possible from areal BMD.
This study also had several limitations. Subjects in this studyself-selected to OC
use thus introducing potential bias between groups. However, inour baseline and 12-
month analysis of typical confounders (e.g. physical activity,strength, dietary intake,
smoking habits, alcohol consumption, menstrual function, andage at menarche) we found
no differences beiween groups except for history of contraceptiveuse. Also, all women in52
this study were college students and thus had similar educational backgrounds. The
differences between groups in change of body weight and leanmass from baseline to
follow-up complicates interpretations. Contrary to the popular belief that oral
contraceptive use can cause weight gain, the oral contraceptiveusers in this study lost
weight in comparison to controls (Table 3.2). Our oral contraceptiveusers lost an
average of 0.8 kg while the control group gained an average of 1.0 kg. Some evidence
suggests that loss of body weight could result in a small measurementerror of BMD via
DXA, indicating bone loss [20-22], however Tothill et aL[19] concluded that the
magnitude of this possible measurement error is small and did not affect results oftwo
clinical studies in which participants lost weight.
Few studies have evaluated OC use and BMD prospectively ina homogeneous
group of young women and those that have provide mixed results. Lloyd et al. [8]
followed adolescent girls prospectively measuring their whole body BMD annually
between the ages of 12 and 20 years. Girls who had begun using oral contraceptivesin
that time period had whole body BMD that was similar tonon-users. There was no
report of the specific dose of OCs, oniy that subjects were using a monophasic pill that
contained less than 50 mcg of ethinyl estradiol foran average of 1.8 years (± 1.3). While
subjects in that investigation were younger thanours, they were similar to our subjects in
that their use of OCs overlapped with the age of peak BMD at all sites.Our controls
increased BMD of the whole body by 0.3% in 12 months while the OCusers showed no
change. Although the differences in bone accrualwere significant between groups in our
investigation, the magnitude of difference was notas large as what we observed at the53
spine. Perhaps Lloyd et al. [8] may have found significant differences ifthey had
measured BMD of the hip and spine.
Reed et al. [11] also reported that oral contraceptiveusers between the ages of 18
and 39 years had no significant differences in change of BMDover 36 months at the hip
and spine, compared with controls.However, when examining the 18 to 21year old
women separately, Reed et al. [11] reported that OC users had a nonsignificant trend for
smaller changes in BMD of the total hip, spine, and whole body after24 and 36 months
of study. Subjects in this study had used OCs foran average of 3.7 years at baseline and
were taking prescriptions with 30-35 mcg of ethinyl estradiol, a dose and length of
exposure comparable to that of our group. The sub-group analysis of 18-21 year-old
women included only 24 OC users and 28 controls. This low number of subjectsmay
have limited the ability to detect the statistically significant differencesin change of
BMD that we found.
In contrast to these results, Recker et al. [2] and Berensonet al. [13] found that
use of oral contraceptives has a positive influence on bone. Reeker et al. [2] reported that
OC use was significantly correlated with gains in whole body bonemineral content (g)
over a 1.4 to 4.0 -year time period but was not related to hipor spine accrual. Their
convenience sample of 156 women was similar toour women in age at the average age of
23.0 (± 1.8) years at baseline. Researchers providedno information on type and duration
of oral contraceptive use, and thus direct comparisonsto our population are difficult.
Berenson et al. [13] reported that women between theages of 18 and 33 who initiated OC
use, on average gained greater BMD at the lumbar spine in comparison to controls.
Women who used norethindronc-containing prescriptions (n-28)gained significantly54
more bone at the AP spine (2.3%) than controls (n=59), whereas BMD gainsdid not
differ between those takinga deogestrel-containing prescription (n=3 5) and controls,
however both types of prescriptions contained 35meg of ethinyl estradiol. In our study,
twO participants at baseline and one at follow-upwere taking norethindrone-containing
compounds while five at baseline and six at follow-upwere taking desogestrel-
compounds. However, all but one of these prescriptionsexcept one paired the
norethindrone or desogestrel with lower estrogen levels (20-30meg) than was used by
Berenson et al (35 meg) [13]. The variation in type ofprogestogens in the OC
prescriptions used by our sample and the small number ofwomen taking each type, did
not allow for evaluation of the effect of differentprogestogens on BMD in our groups.
However, an analysis comparing BMD betweenwomen, taking 35 meg of ethinyl
estradiol (n=l8) and those takingan average of less than 35 meg of ethinyl estradiol
(n=2 1) demonstrated no difference in BMD betweengroups. Further evaluation by
Berenson et al. [9] after 24 months of oral contraceptiveuse showed that changes in AP
spine BMD over the longer period of timewas not significantly different between users
of either type of pill or between OCusers and controls.
Results of Berenson et al.[9, 13] suggest that perhapslonger exposure to
exogenous sources of estrogen from oral contraceptives (> 1 yr) is requiredto detect a
measurable negative effect on BMD. In fact,we evaluated a separate group of "new"
oral contraceptive users (n= 15) whowere within the first 3 months of initiating OCuse at
baseline and we followed them for 12 months. These"new" users did not have
significantly different changes in BMD atany site over 12 months compared to controls.
This also suggests that effects üf OCUseonBMD may lake inure than iyear to manifest.55
Coupled with results of our "new" user group,our data suggests that differences in BMD
accrual, particularly at the spine are related to the long-termuse of oral contraceptives.
Our results support reports from three longitudinal studies. Burret al. [6] and
Weaver et al.[5]examined young (ages 18-31) women witha history of OC use and
controls who initiated a weight-bearing exercise intervention. Comparedto controls,
after 24 months of exercise, OC users demonstratedno change in spine bone mineral
content (g) while the exercising non-users increased by about 2%[5].Women who
neither exercised nor took OCs had the greatest improvements in femoralneck BMD
although changes at 24 months were not significantly different thanexercising or non-
exercising OC users [6]. A high drop out rate may have impacted results of these
analyses. The investigations began with 179[5]and 123 [6] women, however after 24
months sample sizes of55 [5]and 46 [6] remained for analysis. Polatti et al. [7] followed
147 women between the ages of 19 and 23 and found that those who initiateduse of a
monophasic OC, with 20 meg of ethinyl estradiol at the start of the study, maintained
almost constant levels of spinal BMD whilenon-users increased nearly 8%. We report a
1.2% increase in volumetric BMD ofL3in controls over 12 months while OCusers
decreased by 0.8%. However considering theyoung age of their subjects and ours, and
that peak bone mass at the spine is not reached until late in the third decade,a 5-year
follow up with our group may reveal a greater magnitude of differenceas did results from
Polatti et al. [7].
Longitudinal research investigating OCuse and BMD in young premenopausal
women is contradicting. Of the eight studies reviewed here; two founda positive
uiflueuee, iiiree suggested a negative influence, and three reportedno influence of OC56
use on BMD. Differences in results could be due to discrepancies in dose of oral
contraceptives, bone sites measured, age of participants, and length ofexposure to OCs.
Timing of OC use in relationship to peak bonemass attainment at specific sites could
also explain the contradictory findings.
Several studies have shown a decrease in bone formation and resorptionmarkers
in premenopausal women who use oral contraceptives. Specificallyosteocalcin, alkaline
phosphatase, hydroxyproline, and deoxypyridinolineare lower in OC users suggesting an
overall slowing of bone turnover [5, 6, 10, 23, 24]. Inpen- or postmenopausal women,
reducing bone turnover could help preserve bonemass. However, in young women who
are still experiencing skeletal consolidation, a reduction in bone turnover could impede
bone accrual. In our study, perhaps OC users experienced reduced boneturnover while
non-users had normal turnover explaining the differences reported here. Even thoughwe
detected small differences (-3.0% to 1.2%) in bone accrual betweengroups, research of
antiresorption therapies in postmenopausal women suggest thata 1 % increase in BMD of
the hip or spine results in a 10% or 7% reduction in fracturerisk,respectively [25]. If
bone turnover is depressed in young oral contraceptiveusers, many years of exposure, as
experienced by women in this study, could lead to reduced peak bonemass and thus an
increasedriskof osteoporosis later in life.
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Reasons why participants withdrew from the study or were removed from the analysis
ControlsOC Users
N at baseline 40 45
Withdrew
Became pregnant
Stopped using oral contraceptives 2
Started use of hormonal contraception 4
Moved away I
Lost to follow-up 2 2
Removed
Jewelry interference with analysis of BMD atL3 1
Scoliosis did not allow for analysis of BMD atL3 1 2
N included in this analysis 30 39Table 32
Contro]s and women taking oral contraceptives (OC Users)are similar on most variables at baseline and 12month follow-up. At
baseline, OC Users were slightly older than controls and hadbeen taking oral contraceptivesan average of 3.3 years. Over the 12-
month observation period, OC users lost significantlymore weight, specifically lean mass than controls.
Controls (n=30) I OCUsers (n=39)
Baseline 12-month Change Baseline 12-month Change
Age (yrs)* 20.3 ± 1.8 21.2 ± 1.7 0.97±0.06 21.3±1.8 22.3±1.8 0.97±0.03
Height (cm) 166.3±6.5166.2±6.5 -0.1±0.5 167.0±6.4 167.1±6.3 0.05±0.7
Weight(kg) 62.5±8.7 63.5±9.4 1.0±3.1* 65.0±11.1 64.2±10.4 -0.8±3.8
Physical Activity (METs) 58.3±45.655.6±41.8 -2.6±21.1 50.8±37.9 53.2±36.6 2.4±29.2
Grip Strength (kg) 32.1±4.7 32.7±4.8 0.6±2.4 31.3±4.8 32.6±4.4 1.3±2.7
LeanMass(kg) 45.0±5.644.9±5.7 0.1±1.4* 45.8±5.9 44.9±5.6 -1.0±1.7
Percent Body Fat 26.3±4.1 27.1±5.0 0.85 ± 2.39 27.2±5.7 27.7 ± 5.5 0.42 ± 2.85
Calcium Intake (mg/d) 1070± 5511049±768-21.5 ±528.21060± 526 1121 ±54461.1 ±405.7
VitamiDIntake(11J/d) 310± 199304±208 -6.6± 127.7 330±240 302±215 -28.4± 152.5
Years Since Menarche (yrs) 7.5 ± 2.5 8.5 ± 2.5 0.97 ± 0.06 8.3 ± 2.2 9.3 ± 2.2 0.97 ± 0.03
OC Use (yrs)* 0 0 0 3.3 ± 1.8 4.2 ± 1.8 0.97 ± 0.03
Mean ± Standard Deviation
* Significantly differentbetween groups (p<.OS)
-462
Table 3.3
Oral contraceptive doses of ethinyl estradiol (EE) and progestogen (Prog) among women
at visit 1 and 2. Eleven women changed prescriptions in the 12 month time period
between lab visits.
N at Visit 1 N at Visit 2Dose EE (meg)Prog Dose (mg)Type of Prog
2 2 20 0.15 Desogestrel
1 1 20 1.0 Norethindrone
4 5 20 0.1 Levonorgestrel
3 5 25 0.18/0.21/0.25Norgestimate
3 4 30 0.15 Desogestrel
1 2 30 0.15 Levonorgestrel
2 2 30 30 Drospirenone
1 1 30 0.3 Norgestrel
4 1 30/40/30 0.05/0.075/0.125Levonorgestrel
11 9 35 0.18/0.215/0.25Norgestimate
6 7 35 0.25 Norgestimate
1 0 35 0.4 norethindroneTable 3.4
Adjusted change in bone mineral density(BMD) of young women witha history (.5 years) of oral contraceptiveuse (OC users) and regular'y menstruating controls. By analysisof covariance (covariates= age at baseline, change in weight), oralcontraceptive users had greater bone loss atL3in the lateral view (p<O.O5).Controls had greater increases inL3volumetric BMD and of BMDat the total hip and whole body (p < 0.05). Nosignificant differenceswere detected at theL3in the anterior-posterior (AP) view.Total hip and whole body T-scores for bothgroups are positive indicating this isa healthy population.
Controls(n=30) OC Users (n=39)
Bone Site Baseline 12-month
Adjusted
Change Baseline 12-month
Adjusted
Change
L3AP I3MD(g/cm2) 1.112±0.110 1.114±0.108 -0.008 1.082±0.117 1.082±0.117 -0.022
L3Lateral BMD(g!cm2) 0.844±0.105 0.836±0.091 0.004* 0.841±0.088 0.819±0.074 -0.025
L3volumetric BMD(glcm3) 0.242±0.024 0.245±0.019 0.004* 0.242±0.029 0.242±0.024 -0.002
Total Blip BMD(g/cm2) 1.046±0.128 1.056±0.129 0.008* 1.018+0.110 1.023±0.112 0.006
Whole Body BMD(g/cm2) 1.147±0.08 1 1.148±0.083 0.003* 1.127±0.075 1.128±0.075 0.000
Mean ± Standard Deviation
* 12 month changein BMD was significantly differentbetween groups (p<.OS)61t
CHAPTER FOURCONCLUSION
Osteoporosis is a skeletal disease characterized by lowbone mass, predisposing a
person to an increased risk of fracture. This disease is a major healthconcern affecting 44
million people in the United States, eightypercent of who are women (NIH Consensus,
2001). Medical costs for osteoporosisare estimated to total between $10 and $15 billion
each year and the cost is expected to increaseto more than $60 billion by the year 2020.
By the age of 65, only one in ninewomen will have normal bone mass and one in three
will have osteoporosis. A primary strategyto prevent osteoporosis is to developa high
peak bone mass during growth and inyoung adulthood.
Bone mass accrual begins in childhood and continuesincreasing until it reaches a
peak between the ages of 20 and 30, dependingon bone site (Recker et al., 1992). The
NIH consensus panel on osteoporosis (2001)states that someone who does not reachan
optimal peak bone mass during childhoodor adolescence may develop osteoporosis
without experiencing accelerated bone loss. Beginningadulthood with a high peak bone
mass will help protect against osteoporotic fractures when age-related declinesin bone
mass occur. During growth, reproductive hormones playa crucial role in developing an
optimal peak bone mass.
Given the potent role of reproductive hormoneson bone development, the use of
hormonal birth control medication during skeletalconsolidation that occurs in the second
and third decade of life could influence developmentof peak bone mass. Use of
hormonal birth control is a lifestyle habitcommon among young women. Mosher et al.
1fl(l440/.4 ..., 1... I .J IA J L'A/ I_,_i..), r-r/u L1 r-uii.1a1I W'J111I1 uLwi1 i.i inu i' ycwswiu .)LYobetween 20 and 24 years ofage used the pill (Mosher, Deang, & Bramlett, 2003). The
OC pills used by our participants supplementthe body with 20-35mcg of ethinyl
estradiol and progesterone in order tosuppress ovulation and prevent pregnancy. Given
the young age of manywomen using OCs and considering that most of thesewomen are
still accruing bone, supplemented levels ofestrogen and progesterone in OCsmay affect
bone mineral accrual and ultimately influencepeak bone mass.
Our aims were to 1) compare bone mineraldensity of young women who hada
history of OC use with regularly menstruatingcontrols, 2) compare changes in BMD in
controls, women who initiate OCuse, and those who have a history of use, and 3) to
evaluate predictive capabilities of physicalactivity and years of oral contraceptivesuse
on changes in BMD. We found that use of oral contraceptives duringlate adolescence
may alter bone metabolism and thus reduce peak bonemass in young women. We report
that controls between theages of 18 and 25 have 1.0-2.6% greater BMD at the spine,0.8-
1.8% greater BMD at the hip, and 1.1%greater whole body BMD than oral contraceptive
users of the same age. We also found thatyoung women with a history of oral
contraceptive use have significantly differentchanges in BMD over 12 months than
controls and this difference is most pronouncedin the vertebral bodies. Specifically, OC
users lost 3.0% of lateral spine BMD while controls lost 0.5%BMD, OC users lost 0.8%
while controls gained 1.2% volumetric BMDof L3. Women who initiated oral
contraceptive use at the start of the study didnot have significantly different changes in
BMD compared to controls. Perhaps longerexposure to exogenous sources of estrogen
from oral contraceptives (> I yr) is requiredto detect a measurable effect on BMD.67
We conducted stepwise regressions to evaluate predictivecapabilities of
independent variables on 12-month changes in BMD ofOC users. Variables included in
the analysis were: 1) yearson oral contraceptives, 2) body mass index 3) calcium intake,
4) grip strength, and 5) physical activity. Results didnot reveal years of oral
contraceptive use, grip strength, or physical activity in METsto be a significant predictor
of changes in BMD at any site.
Perhaps the relationship betweenyears of OC use and changes in BMD is non-
linear. Our results and those of others (Berenson, Breitkopf,Grady, Rickert, & Thomas,
2004) suggest that at least oneyear exposure to OCs is necessary to detect differences in
bone accrual. It is possible thata minimum amount of exposure is required to elicitan
effect on bone creating a relationship betweenyears of OC use and changes in BMD that
is non-linear. Our lack of findings in the regressionequation may be due to 20 ofour OC
users having taken their prescription for 1.5 yearsor less. Inherent errors in measuring
physical activity with a self-reporting questionnairemay also limit our findings.
Osteoposorosis is a major healthconcern affecting millions of American women
each year. We report that oral contraceptiveuse early in life may be detrimental to bone
health and limit development of peak bonemass. This raises concern for the large
numbers of women using oral contraceptives beforeattaining peak bone mass. Estrogen
doses of oral contraceptives have dropped significantlysince their introduction in the
1960's. The type of estrogen used has moved frommestranol to ethinyl estradiol, with
greater metabolic activity. In most recentyears the trend toward very low-dose oral
contraceptive is evident. Today's prescriptionsmay contain as low as 20 mcg of ethinyl
estradiol and arc still cffcctivc in preventing ovuiatiuii.These low-dose prescriptionsmay be high enough to suppress endogenous estrogen productionand prevent pregnancy
but may be too low to optimally activatecellular bone activity. Evidencesuggests that
bone turnover is slowed inwomen on oral contraceptives (Nappi et al., 2003). Perhaps
the low-dose prescriptions used todaysuppress bone modeling and remodeling. The type
of progesterone in oral contraceptiveprescriptions should also be considered.Some
evidence suggests that certain types ofprogesterone in oral contraceptive prescriptions
may inhibit endogenous estrogen production toa greater extent (Elomaa et al., 1998).
Perhaps these progetogens should be avoidedin women who are at risk for osteoporosis.
Many of the women in our study reportedusing the pill for non-contraceptive benefits,
such as acne control. Given the variety ofnon-hormonal medications foracne control, it
seems prudent for physicians to recommend theseover OCs.
With nearly half of Americanwomen between the ages of 15 and 24 using oral
contraceptives, their impact on peak bonemass development needs to be further defined.
At initial measurements, results showed thatwomen with a 3-year history of OC use, had
1-3% lower BMD compared to controls.Furthermore, after 12-months, the OCusers
gained bone at a slower rate than controls.Depending on how long thesewomen use oral
contraceptives they may be ata great disadvantage later in life.Our findings warrant
further investigation. A randomized controltrial of oral contraceptiveuse in
prernenopausal women would help to addresscontradictory findings and reduce self-
selection bias. Also measurement ofhormone levels and bone markers would helpto
identify an optimal dose of ethinyl estradioland type of progestogen that donot inhibit
peak bone mass development inyoung women.BIBLIOGRAPHY
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APPENDIX A: REVIEW OF LITERATURE74
Background
Osteoporosis is a skeletal disease characterized by low bone mass, predisposing a
person to an increased risk of fracture. This disease is a major health concern affecting 44
million people in the United States, eighty percent of who are women (NIH Consensus,
2001). Medical costs for osteoporosis are estimated to total between $10 and $15 billion
each year and the cost is expected to increase to more than $60 billion by the year 2020
(NIH Consensus, 2001). A primary strategy to prevent osteoporosis is to develop a high
peak bone mass during growth and in young adulthood.
Bone mass accrual begins in childhood and continues increasing until it reaches a
peak between the ages of 20 and 30, depending on bone site (Recker et al., 1992).
Specifically, Theintz et al. (1992) found peak bone mass at the femoral neck in young
women to be complete by age 16 whereas Recker and colleagues (1992) found peak
whole body bone mineral content is attained at age 29.5, while spinal peak BMD occurs
at age 28.5. The NIH consensus panel on osteoporosis (2001) states that someone who
does not reach an optima! peak bone mass during childhood or adolescence may develop
osteoporosis without experiencing accelerated bone loss. A higher peak bone mass in
childhood will help protect against age-related declines in bone mass. Some researchers
even consider osteoporosis a childhood disease manifested in adults. During growth,
reproductive health, exercise, and nutrition are all important factors that help in
developing an optimal peak bone mass.
Given the potent role of reproductive hormones on bone development, the use of
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and third decade of life could influence development of peak bonemass. Use of
hormonal birth control is a lifestyle habit commonamong young women during this time.
In 1995, 44% of American women between 15 and 19years and 52% between 20 and 24
years of age used the pill (Mosher, Deang, & Bramlett, 2003). Oral contraceptive pills
are the most popular method of reversible contraception in the US, withmore than 16
million users. Most OC pills supplement the body with bothestrogen and progesterone
in order to suppress ovulation and preventpregnancy. Given the young age of many
women using OCs and considering that most of these women are still accruing bone,
supplemented levels of estrogen and progesterone in OCsmay affect bone mineral
accrual and ultimately influence peak bone mass.
Research thus far is equivocal regarding the influence of hormonalbirth controls
on bone health. Type of hormones, different dosage, method of delivery, length of birth
control use, and age at onset of use are all factors that contributeto the contradicting
nature of research to date. It is well documented that estrogen deficiency is associated
with bone loss. Studies of postmenopausalwomen and amenorrheic women have
demonstrated significant loss of bone mineral density (BMD) in the absenceof estrogen
(Drinkwater et al., 1984; Johnston et al., 1985; Ohta et al., 1993; Rencken,Chesnut, &
Drinkwater, l996). Although the mechanism between estrogen and boneis still unclear,
it is evident that estrogen has a complex interaction with bone throughspecific cell
receptors influencing bone metabolism.
The usual dosage of estrogen replacement therapy is about 1.25mg per day of
estrogen, while the dosage of estrogen found in most combined OCsranges between 0.20
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however the progesterone compoundsvary greatly between different prescriptions in
dosage and chemical variety. Thereare monophasic and triphasic OC medications
available. The monophasic prescriptions supplement the bodywith one dose of estrogen
and progesterone for 21 days to prevent ovulation whilethe triphasic type gives three
different doses of estrogen and progesteroneover the course of 21 days. There are also
non-oral types of birth control that contain onlyprogesterone compounds. Two common
examples of these types of birth controlare depot medroxyprogesterone acetate (DMPA)
and levonorgestrel implants. These twotypes of birth control slowly release
progesterone in order to prevent ovulation (Bahamondeset al., 1999; Beerthuizen et al.,
2000).
Although estrogen replacement therapy in postmenopausalwomen has been
shown to prevent bone loss, the effect of low-doseestrogen from OCs on bone during
normal ovarian function is poorly understood. Because ofdifferences in endogenous
sources of hormones, comparisons of research between postrnenopausalwomen and
premenopausal women are difficult to interpret. Few researchstudies have examined the
effects of different doses and types of OCson bone and since the literature is still
controversial on this topic, thereare few data that report a possible interaction between
OC, BMD and physical activity. It is unknown whetherexposure to low doses of
estrogen and progesterone as in OC medications affect bone metabolismin young
women.77
Perimenopausal and Postmenopausal Oral Contraceptive Use andBone
It appears that previous OC use studied in perimenopausal andpostmenopausal
women has a protective effect on bone (Corson, 1993; Kuohung, Borgatta, &
Stubblefield, 2000). One case-control study of premenopausalwomen report a positive
association between OC use and BMD (Lindsay, Tohme, & Kanders,1986). A few
prospective studies of premenopausal women have founda positive influence of OCs on
bone (Recker et al., 1992; Shargil, 1985), while others havenot (Mazess & Barden,
1991).
Gambacciani, Spinetti, Cappagli et al. (1994) conducteda randomized prospective
study of OC use and calcium supplementation in 32 perimenopausalwomen between the
ages of 40 and 48. Perimenopausal status was defined as oligomenorrhea in the previous
3 to 6 months before entering the study. Through random assignment,half of the
participants were supplemented with 500mg calcium while the other half were give 30
meg ethinyl estradiol plus 75 meg gestodene. Measurements of radial BMDwere
performed at baseline and every 6 months for 2years by dual photon absorptiometry.
Biochemical analysis included hydroxyproline, plasma bone Glaprotein, serum alkaline
phosphatase, and plasma estradiol. Results showed that BMD of theradius significantly
increased by almost 2% over the course of 2years, in the group treated with OCs. In the
group supplementing with calcium, BMD showed a significant decrease of 2% after24
months.78
Biochemical markers supported the BMD results indicatinga significant increase
in bone turnover for the group taking calcium while theOC group showed a decrease in
bone turnover. Investigators concluded that administration of30 meg ethinyl estradiol
and75mg gestodene could prevent activation of bone turnover and the decrease in BMD
associated with oligomenonhea observed in perimenopausalwomen.
In another similar study, Gambacciani, Spinetti, Taponecoet al. (1994) reported
that low-dose OC use inhibited bone resorption in oligomenorrheic,perimenopausal
women. This study also used a prospective randomized design, however, in this
investigation, 27 age-matched eumenorrheic controlswere recruited to compare with the
treatment groups. Oligomenorrheic perimenopausalwomen in this study were randomly
assigned to groups receiving 500 mg of calciumor an OC containing 20 meg ethinyl
estradiol plus0.15mg desogestrel. Bone mineral density of the second through fourth
lumbar vertebrae was assessed using themore advanced dual-energy x-ray
absorptiometry (DXA) technology. Bone metabolism markers(hydroxyproline and
osteocalcin) and hormone levels (FSH and estradiol)were also assessed. Measurements
were performed at baseline and every 6 months for 2 years.
Hormone assay results showed that oligomenorrheicwomen not taking OCs had a
greater cycle length characterized by a significant rise in FSH levelsand a decline in
estradiol levels over the 2 year period. The rise in estradiol levelscorresponded with an
increase in plasma osteocalcin and urinary excretion of hydroxyproline,indicating
increased bone turnover. The eurnenorrheic controls showedno significant changes in
hormone or bone metabolism markers. The oligomenorrheicwomen taking calcium only
showed a significant dcclinc in BMD of 4.4% iwoyears after baseline, whiie the79
eumenorrheic controls showed no change. On the contrary, the 27 oligomenorrheic
women who began taking OCs actually showed an increase in BMD of 2.4% at the spine
after 24 months. These results compliment the results of the previously discussed
investigation and indicate that OC use in perimenopausal womenmay help prevent bone
loss.
The studies of Gambacciani et al.(Gambacciani, Spinetti, Cappagli et al., 1994;
Gambacciani, Spinetti, Taponeco et al., 1994) are stronger than other research in thisarea
due to their randomized intervention design and because specific doses of OCswere
used. These studies were prospective in nature andwomen had no previous history of
OC use or HRT use, Furthermore in the work of Gambacciani et al., menstrual status
was confirmed with hormone levels and biochemical markers strengthened the BMD
results. These studies lead one to believe there may be a protective effect of OCuse on
bone. These studies were conducted in perimenopausal women, which do not help
answer the question of how OC use affects attainment of peak bone mass by young
women.
Cross Sectional Investigations
Prior et al. (2001) conducted a multi-center trial of over 500women between the
ages of 25 and 45 years. They reported that BMD of the hip and spine was lower in
premenopausal women who used OCs for3 months in comparison to women who had
never used OCs. Their results demonstrated that women who had never used OCs had3.6%, 5.5%, and 4.6% greater BMD than current OC users at the femoral neck,
trochanter, and AP spine, respectively.
Some investigations report no differences in bone, mass between OC users and
controls (Garnero, Sornay-Rendu, & Delmas, 1995; Lloyd et al., 1989). Garnero et al.
(1995) reported no differences in BMD of the hip, spine or whole body between 52
premenopausal OC users and 156 controls (ages 35-49 years). However, Gamero et al.
(1995) did detect significant differences in bone markers indicating thatwomen taking
OCs with 30 meg of ethinyl estradiol had lower resorption and formation markers than
controls. The OC users of Garnero et al. (1995) were closer to peak bone mass (39.3
years) and started taking oral contraceptives in young adulthood (average history= 6.7
years). Thus it is possible that the influence of OCs on bone is not relevant after skeletal
consolidation. Lloyd et al. (1989) found that trabecular bone density of the lumbar spine,
measured by quantitative computed tomography, was similar in between 11 OCusers and
14 controls early in the fourth decade of life. Researchers did not report physical activity
or nutrient intakes that could significantly alter results.Results of Lloyd et al. (1989)
may be contradicting to others because 1) they employed different techniques for
measuring BMD than us, 2) their OC users were taking 50 meg mestranol whileours
were taking 20-35 meg ethinyl estradiol, and 3) their women were older (31-33 vs. 21)
and started taking OCs at a later age (26 vs. 18) than our subjects.
One cross-sectional study reports a positive association between exposure to OCs
and BMD of the spine. Pasco et al. (2000) investigated OC use and BMD in 710women
between the ages of 20 and 69 years. In a separate analysis of premenopausalwomen,
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differences were detected at the hipor whole body. The average age at first exposure to
OCs was 21.1 ± 5.7 years which hadno detectable effect on current BMD. Investigators
did not specify the dose of OC medications being usedby their participants.
Longitudinal Investigations
Few studies have evaluated OCuse and BMD prospectively in premenopausal
young women and those that have provide mixed results. Lloyd et al. (2000) followed
adolescent girls prospectively measuring their whole bodyBMD annually between the
ages of 12 and 20 years. Girls who had begun using oral contraceptives in thattime
period had whole body BMD thatwas similar to non-users. There was no report of the
specific dose of OCs, only that subjectswere using a monophasic pill that contained less
than 50 mcg of ethinyl estradiol foran average of 1.8 years (± 1.3). Subjects in that
investigation were young and theiruse of OCs overlapped with age of peak BMD at all
sites. Perhaps Lloyd et al. (Lloyd et al., 2000)may have found significant differences if
they had measured BMD of the hip and spine.
Reed et al. (2003) also reported that oral contraceptiveusers between the ages of
18 and 39 years had no significant differences in change ofBMD over 36 months at the
hip and spine, compared with controls.However, when examining the 18 to 21year old
women separately, Reed et al. (2003) reported that OC users hada nonsignificant trend
for smaller changes in BMD of the total hip, spine, andwhole body after 24 and 36
months of study. Subjects in this study had used OCs foran average of 3.7 years at
baseline arid were taking prescriptions with 30-35mcg of ethinyl estiadloi, adose andlength of exposure comparable to that ofour group. The sub-group analysis of 18-21
year-old women included only 24 OCusers and 28 controls. This low number of subjects
may have limited the ability to detect the statistically significant differences in change of
BMD that we found.
In contrast to these results, Recker et al. (1992) and Berensonet al. (2001) found
that use of oral contraceptives hasa positive influence on bone. Recker et al. (1992)
reported that OC use was significantly correlated with gains in whole bodybone mineral
content (g) over a 1.4 to 4.0 -year time period but OCuse was not related to hip or spine
accrual. Their convenience sample of 156women was the average age of 23.0 (± 1.8)
years at baseline. Researchers provided no information on type and duration of oral
contraceptive use, and thus direct comparisons to other populationsare difficult.
Berenson et al. (2001) reported thatwomen between the ages of 18 and 33 who initiated
OC use, on average gained greater BMD at the lumbar spine incomparison to controls.
Women who used norethindrone-containing prescriptions(n=28) gained significantly
more bone at the AP spine (2.3%) than controls (n=59), whereas BMD gains didnot
differ between those taking a desogestrel-containing prescription(n=35) and controls,
however both types of prescriptions contained 35mcg of ethinyl estradiol. Further
evaluation by Berenson et al. (2004) after 24 months of oralcontraceptive use showed
that changes in AP spine BMDover the longer period of time was not significantly
different between users of either type of pillor between OC users and controls. Results
of Berenson et al.(2001) suggest that perhaps longerexposure to exogenous sources of
estrogen from oral contraceptives (> I yr) is required to detecta measurable negative
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Three longitudinal studies report that OCuse has a negative on bone in healthy
premenopausal women. Burr et al. (2000) and Weaveret al. (2001) examined young
(ages 18-31) women with a history of OCuse and controls who initiated a weight-bearing
exercise intervention. Compared to controls, after24 months of exercise, OCusers
demonstrated no change in spine bone mineralcontent (g) while the exercising non-users
increased by about 2% (Weaver et al., 2001).Women who neither exercisednor took
OCs had the greatest improvements in femoral neckBMD although changes at 24 months
were not significantly different than exercisingor non-exercising OC users (Burr et al.,
2000). A high drop out ratemay have impacted results of these analyses. The
investigations began with 179 (Weaver et al., 2001)and 123 (Burr et al., 2000)women,
however after 24 months sample sizes of 55(Weaver et al., 2001) and 46 (Burr et al.,
2000) remained for analysis. Polatti et al.(1995) followed 147 women between theages
of 19 and 23 and found that those who initiateduse of a monophasic OC, with 20 meg of
ethiny! estradiol at the start of the study, maintainedalmost constant levels of spinal
BMD while non-users increased nearly 8%.Considering the young age of their subjects
and that peak bone mass at the spine isnot reached until late in the third decade, the
timing and duration of OCuse could explain their results (Polatti et al., 1995).
Longitudinal research investigating OCuse and BMD in young premenopausal
women is contradicting. Of the eight studies reviewed here;two found a positive
influence, three suggested a negative influence, andthree reported no influence of OC
use on BMD. Differences in results could be due to discrepanciesin dose of estrogen in
the oral contraceptives, type ofprogesterone, bone sites measured,age of participants,and length of exposure to OCs. Timing of OCuse in relationship to peak bone mass
attainment at specific sites could also explain the contradictoryfindings.
Physical Activity, Bone and OC Use
The literature supports a strong positive relationshipbetween high levels of
weight-bearing activity and greater bonemass. This has been demonstrated in research
of highly weight-bearing activities, suchas gymnastics. Taaffe et al. (Taaffe, Robinson,
Snow, & Marcus, 1997; Taaffe et al., 1995) foundsignificantly greater BMD in college-
age gymnasts when compared to controls, swimmers, andrunners. Robinson et al.
(1995) found gymnasts to display greater BMD thanrunners despite similar prevalence of
menstrual irregularities. One wouldassume that since weight-bearing exercise improves
BMD and OC use may help maintain healthy bones,the two in combination would
synergistically improve BMD, however this has not beenreported. Two studies have
examined the relationship between exercise andOC use on BMD.
Results from Weaver et al. (2001) and Burret al. (2000) discussed earlier suggest
a negative interaction between oral contraceptiveuse and physical activity on bone
health. Results from Hartard et al. (1997)support this. Hartard et al. (1997) performeda
cross-sectional analysis of BMD at the hip and spine in 128women between the ages of
20 and 35. Participants were divided into 4groups depending on the years of regular
physical activity and years of OCuse. Someone was placed in the high physical activity
groups if she exercised more than 2 hours per week formore than 3 years. Women were
categorized as having a long-tcrmCxpOSUrC to OCs if they had takcii ojal eoiiiraeepiivepills for at least 3 years. The fourgroups created were; 1) high exercise and short OC, 2)
high exercise and long OC, 3) low exerciseand long OC, and 4) low exercise and short
OC. Group 1 displayed the highest BMDat all sites measured, including both rightand
left hips and in anterior/posterior and lateralviews of the spine. When compared with
group 2, the participants with shortexposure to OCs had up to 8% greater BMD at the
spine and 7% greater BMD at both right andleft femoral necks. Theaverage age of
participants was 28.3 ± 3.6years and no significant difference inage was seen between
groups.
Current literature shows that high levels of physicalactivity are associated with
high measurements of BMD; however thiswas not the case in the group of women
characterized by high exercise while takinglow-dose OCs for more than 3years. Hartard
et al. (1997) suggested that low-dose OCs mightcounteract the beneficial influence of
exercise on bone formation. The lack ofinformation provided for diet, type of OC,and
duration and type of physical activity limitsconclusions from the findings. The absence
of comparisons with control participantsnot taking OCs limits the findingsas well.
Many researchers in the area of exercise physiologymay not consider exercising more
than 2 hours a week,very active. This does not allow for comparisons withvery athletic
women who exercise many hours per week formany years.
Rationale
Several studies have showna decrease in bone formation and resorption markers
in prernenopausalwomen who use oral contraceptives. Specifically osteocalcin,alkaline
phosphatase, hydroxyproline, and dcoxypyridinolincare lower in OC users suggestinganoverall slowing of bone turnover (Burret al., 2000; Garnero et al., 1995; Mais et al.,
1993; Nappi et al., 2003; Weaver et al., 2001). Inpen- or postmenopausal women,
reducing bone turnover could helppreserve bone mass. However, in young women who
are still experiencing skeletal consolidation, a reduction in boneturnover could impede
bone accrual. Several of these studies reviewedhere detected small differences (0%to
8%) in bone accrual betweengroups, research of antiresorption therapies in
postmenopausal women suggest thata 1% increase in BMD of the hip or spine results in
a 10% or 7% reduction in fracture risk, respectively (Wasnich &Miller, 2000). If bone
turnover is depressed in young oral contraceptiveusers, many years of exposure, could
lead to reduced peak bonemass and thus an increased risk of osteoporosis later in life.
The work cited in the previous section demonstratesthat exercise and OC usemay have a
complex interaction with bone that is poorly understood.There is limited research
examining the effects of initiating OCuse on BMD especially in young healthy
prernenopausal women. Considering theage overlap between skeletal consolidation and
OC use, it is important to define the potentialrole of OC use and exercise in modifying
bone.APPENDIX B: INFORMED CONSENT DOCUMENTS['I']
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implemented. Immediate action may be taken wherenecessary to eliminate
apparent hazards to subjects, but this modification to the approved projectmust be
reported immediately to the IRB.
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Project Title: Potential Influences of Oral Contraceptive Use and Physical
Activity Bone Health: A One-Year Prospective Study in Young
Women
Principal Investigator: Dr. Christine Snow
Student Researcher:Hawley Almstedt
PURPOSE
The purpose of this research study is to learn more about the influence of oral
contraceptive use and physical activity on bone. The purpose of this consent
form is to give you the information youwillneed to help you decide whether to
be in the study or not. Please read the form carefully. You may ask any
OREGON questions about the research, what you will be asked to do, the possible risks and
STATE benefits, your rights as a volunteer, and anything else about the researchor this
form that is not clear. When all of your questions have been answered,you can
decide if you want to be in this study or not. This process is called "informed
consent". You will be given a copy of this form for your records.
214 ll We are inviting you to participate in this research study because youare an
Corva1ti. Oregon Oregon State University student between the ages of 18 and 25. Youare either
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taking an oral contraceptive specifically, Ortho-Cyden, Ortho-Tricyclen,or
Miciette), or are participating as a control. We expect 120 women to participate
in this study. This study will serve as a dissertation project for the student
investigator and it is the hope of researchers to seek publication.
PROCEDURES
If you agree to participate, your involvement will include two lab visits lasting
one hour each. You will visit the Bone Research Lab once in the Fall of 2003
and then again in the Fall of 2004. If you are taking oral contraceptivesyou will
be asked to check in with us monthly via email or telephone. You will hc asked
to reply to an email or voice message letting us know if you missed a pill in the
previous month or if you have stopped taking or switched oral contraceptive
prescriptionslfyour status as an oral contraceptive user or non-user changes
during the 12-months you may no longer he eligible to participate in the study.
The following procedures are involved in this study. You will complete
541"'643 questionnaiies'asking about nutrition, eating habits, physical activity, medical
and menstrual history. These questionnaires may be completed in the
i-AX lab during your visit or at home from a websitc. You will have height, weight,
541-737-2795 grip-strength assessments, and hone denstty testing. The bone densityscan takes
about 25 minutes and requires that you lie still on a pai.kled table vli lIe thescan
is pertormcd Three scans will be performed (hip, spine, and whole body) at
cacti visit (now and in 12 months). In between visits to the lab, part cipants
tk ing oral coultrdCepl i yes will be asked to return cm in Is i nclicating whetheror
not they had01isscd a pu1 or changed pu esLriptions in the previouiiiontli.If any
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participant cannot be reached by email, she will be telephoned. Each of thesetests will be
repeated in the Fall of 2004
RISKS
The possible risks associated with participating in this research projectare as follows. There is a
risk of radiation exposure from the bone scan. You may not receivea bone scan if you are
pregnant or suspect that you may be pregnant. If you are not currently using an oral
contraceptive, the bone scan must be performed within the first ten days of the beginning ofyour
last menstrual period. This will reduce theriskof performing the scan on a developing embryo.
You must inform the researchers if there is a chance that you may be pregnant. Ifyou have
irregular or erratic cycles you may be asked to take a pregnancy test before the bonescan will be
performed. The hip, spine, and whole-body scans together deliver a total (0.585 mrem) effective
dose equivalent less than the radiation exposure from a chest x-ray (5.0 mrem)or a flight across
the country (4.0 mrem). Therefore the three scans will be performed twice, with 12 months in
between, in this study result in a radiation dose less than a chest x-rayor an airline flight across
the country. There are risks involved with sending medical information via email. Email
transmission cannot be guaranteed to be secure or error-free and it is possible thatmessages
could be intercepted, corrupted, lost, destroyed, arrive late or incomplete,or contain viruses.
BENEFITS
The potential personal benefits that may occur as a result of your participation in this studyare
an accurate measurement of your bone mineral density and body composition free of cost. You
will also receive a nutritional analysis based on results from completed questionnaires.You will
receive this infonl1ation at the end of the study. The researchers anticipate that societymay
benefit from this study by better understanding whether oral contraceptiveuse can affect bone
health in young women. If you have a decrease in bone mineral density ofmore than 5% in a
one-year period, you will be encouraged to see your physician concerning the results.
COMPENSATION
You will not have any costs for participating in this research project. You will be compensated
$50 for participating in this rescarch project at the time of your second visit. Anyone who does
not return for a second testing session will not be compensated. Voluntecrs who withdraw from
the study or no longer lit the study criteria will not be given compensation.
CONFIDENTIALITY
Records of participation in this research project will be kept confidential to theextent permitted
by law. However, federal government regulatory agencies and the Oregon State University
Institutional Review Board (a committee that reviews and approves research studies involving
human subjects) may inspect and copy records pertaining to this research.It is possible that
these records could contain infbrination that personally identities you. Participants will he
assigricd a subject number, whichIsused on all computer data, questionnaires, and bone elensity
pr utouts. Only the pri nd pal investigators will have know ledge of each subject's name and
identification number. All records will be stored in a locked tiling cabinet wlii Icnot in use. In
the event of any report or publication from this study, your identity will not be disclosed.
Results will he rcpuirtcul in a summarized manner in such a way that you cannot he identified.
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RESEARCH RELATED INJURY
In the event of research related injury, compensation and medical treatment are not provided by
Oregon State University.
VOLUNTARY PARTICIPATION
Taking part in this research study is voluntary. You may choose not to take part at all. Ifyou
agree to participate in this study, you may stop participating at any time. For all questionnaires,
you may skip any questions that you prefer not to answer. If you decide not to take part, or if
you stop participating at any time, your decision will not result in any penalty or loss of benefits
to which you may otherwise be entitled. You will receive your nutrition analysis, bone scan, and
body composition results if you choose to withdraw early. Data collected prior to withdrawal
may be included in the study results.
QUESTIONS
Questions are encouraged. If you have any questions about this research project, please contact:
Dr. Christine Snow at 541 -737-6788, 106 Women's Building, Oregon State University or
Hawley Almstedt at 541-737-3094, 13 Women's Building, Oregon State University. Ifyou have
questions about your rights as a participant, please contact the Oregon State University
Institutional Review Board (IRB) Human Protections Administrator, at (541) 737-3437or bye-
mail at IRBiäioreconstate.edu.
POTENTIAL FOR FOLLOW-UP STUDIES
There is a chance you may be contacted in the future to participate in an additional study related
to this project. If you would prefer not to be contacted, please let the researcher know, at any
time.
Your signature indicates that this research study has been explained to you, thatyour questions
have been answered, and that you agree to take part in this study. You will receivea copy of this
form.
Participant's Name (printed):
(Signature of Participant) (Date)93
APPENDIX C: Medical, Menstrual, Physical Activity, and Nutrition
Questionnaires94
Medical History Questionnaire
Oral Contraceptive Study
Last Name First Name MI
School Address
Date of Birth
City, State, Zip
School Phone Work/Cell Phone Email Address
Permanent Address City, State, Zip
How do you prefer to be contacted regarding this study?
U Email Permanent Home Phone
U Phone
UOther
Which describes your ethnic cateorv?
o Not Hispanic or Latino
oHispanic or Latino: A personofCuban, Mexican, Puerto Rican, South or Central
American, or other Spanish culture or origin, regardlessofrace. The term, "Spanish
origin, "can be used in addition to "Hispanic or Latino"
ciDecline to respond
Which describes your racial categories? (Check all that apply)
oWhite: A person having origins in anyofthe on ginal peoplesofEurope, North Africa, or
the Middle East.
oAsian: A person having origins in anyofthe original peoplesofthe Far East, Southern
Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan,
Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
ciBlack or African American: A person having origins in any of the black racial groups of
Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African
American ".
oNative Hawaiian or Other Pacific Islander: A person having origins in any of the
on gina! peoples of Hawaii, Guam, Samoa, or other Pacflc Islands.
ciAmerican Indian or Alaska Native: A person having origins in any of the original
peoples of North, central, or South America and maintains tribal affiliation or
rr),n flhlfl7/1)
oDecline to respond95
Past History: Do you or have you ever had? (Check if yes)
LiHigh blood pressure 0 Back injury LiDiabetes
oHeart trouble LiDisease of the arteries LiEpilepsy
LiMusculoskeletal injury 0 Lactase Deficiency 0 Stroke
LiLung disease 0 Broken bones 0 Other
illness/disease
LiHigh or low thyroid LiHigh Cholesterol 0 Other operations
If yes to any of the above, please explain:
Present Symptoms: Have you had in the past 6 months? (Check if yes)
oChest pain LiBack pain
oShortness of breath LiPainful, stiff or swollen joints
If yes to any of the above, please explain:
General Questions
Do you drink alcohol? Yesor No
Do you drink two or more drinks per day? YesorNo
Do you currently smoke tobacco?Yesor No
Do you smoke more than 10 tobacco cigarettes a day?YesorNo
Were you a tobacco smoker in the past?YesorNo
If you have quit, when did you quit?
For how long did you smoke tobacco?
Didyou smoke morethan 10 tobacco cigarettes a day?Yes orNo
Are you taking any prescription medications other than oral contraceptives?
Yesor No96
Menstrual History Questionnaire
Oral Contraceptive Study
1. Are you currently taking oral contraceptives?Yes or No
(if NO proceed to question #2)
.What is the prescription name?
How long have you taken this prescription?
What was your reason for initiating oral contraceptive use?
oContraception
oProvide menstrual regularity
oManage acne
oOther:
Have you taken any other oral contraceptive prescriptions in the past? YesorNo
If yes, what was the prescription name and how long did you take this product?
In the past year, has there been a period of time longer than one week that you did not
take your oral contraceptives (not including the inactive week of pills)?Yes or No
If yes, when, and please explain
2. Have you used any other hormonal birth control besides oral contraceptives since your last
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Yesor No97
3. Please check the box of the response that best describes your menstrual history in thepast
year.
U 10- 12 periods per year - Regular
U 4- 9 periods per year - Oligomenorrhea
U Less than 3 cycles per yearAmenorrhea
4. Are you currently pregnant?Yesor No
NOTICE: The radiation exposure from the bone scan may be harmful toan unborn
baby therefore it is dangerous for someone to proceed with the testing if she is
pregnant.
5. Is there any chance you could currently be pregnant?YesorNo
If your pregnancy status is unknown or if there any chance thatyou could currently be
pregnant, please notify the researcher. All information will be kept confidential.
6. When was the first day of your last menstrual cycle?98
Exercise and Physical Activity Questionnaire
Oral Contraceptive Study
Please circle YES for all that apply and NO if you do not perform the activity; provide
an estimate of the amount of activity for all marked YES. Try to be as complete as
possible.
For the last three months, which of the following moderateor vigorous activities have
you participated in regularly (at least once a week)?
Walking
NOYES-* How many sessions per week?
How many miles (or fractions of) per session
Average duration per session? (in minutes)
What is your usual pace of walking? (check one)
U Casual or strolling (<2 mph)
U Average or Normal (2 to 3 mph)
U Fairly Brisk (3 to 4 mph)
U Brisk or Striding (4 mph or faster)
Stair Climbing
NOYES-* How many flights of stairs do you climb UP each day?
(1 flight = 10 steps)
Jogging or Running
NOYES-* How many sessions per week?
How many miles (or fractions of) per session
Average duration per session? (in minutes)
Treadmill
NOYES-* How many sessions per week?
How many miles (or fractions of) per session
Speed? (mph) Grade? (%)
Bicycling
NOYES-* How many sessions per week?
How many miles (or fractions of) per session
Average duration per session? (in minutes)99
Swimming
NOYES How many sessions per week?
How many miles (or fractions of) per session
(880 yards=0.5 miles)
Average duration per session? (in minutes)
Aerobic Dance/Calisthenics
NOYES-*How many sessions per week?
Average duration per session? (in minutes)
Moderate Sports
[e.g. volleyball, golf (no cart), social dance, doubles tennis, softball)]
NOYES-pHow many sessions per week?
Average duration per session? (in minutes)
Vigorous Racquet Sports
(e.g. racquetball, singles tennis)
NOYES How many sessions per week?
Average duration per session? (in minutes)
Other Vigorous Sports or Exercise Involving Running
(e.g. basketball, soccer, ultimate frisbee)
NOYES-+Please Specify
How many sessions per week?
Average duration per session? (in minutes)
Other Activities
NOYES-Please Specify
How many sessions per week?
Average duration per session? (in minutes)
Weight Training (machines and free weights)
NOYES-*How many sessions per week?
Average duration per session? (in minutes)
Household Activities
(Sweeping, vacuuming, washing clothes, scrubbing floors)
NOYES-*How many hours per week?
Lawn Work Gardening
NOYES-*How many hours per week?
How many times a week do you engage in vigorous physical activity
1nncenniwhthwnrk uncweit9 -
(times per week)RESPONDENT ID
NUMBER TODAY'S DATE
oJanDAYYEAR
OFeb
OMar®®19980
OApr DW19990
0 May O?i? 20000
0 Jun cDO 2001 0
OJulU?20020
OAugD20030
OSep 20040
OOctW20050
ONov®20060
ODec D20070
This form Is about the foods you usually eat.
It will take about 30- 40 minutes to complete.
Please answer each question as best you can.
Estimate if you aren't sure.
Use only a No. 2 pencil.
Fill In the circles completely, and erase
completely If you make any changes.
100
FOOD:
QUESTIONNAIRE:
SEX AGE WEIGHTHEIGHT
0 Male pounds ft
0 Female
I 11
lffemale,areyou DW ODWcD
pregnant or cDtD cDciicD breast feeding? _______ Qc2 cDcDO
0 No j c22cD®®® c009
OYes jcDJ c2c Please print your name in this box.
0 Not female ®E9 ®®
0cz9 cDcD
®D c1D 1951
cic51I t®
tisI
©
First, a few general questions
about what you eat. ONCE
per
WEEK
Ido you eat, per day or per week, not 00
I 000000 counting salad or potatoes?
IAbout how many servings of fruit do you000000000
I About how many servings of vegetables
I I
jeatHow
often do you use fat or oil in cooking?000 000
not counting juices?
How often do you eat cold cereal? 000000000
What kinds of fat or oil do you usually use in cooking? MARK ONLY ONE OR TWO
0 Don't know, or Pam 0 Butter/margarine blend0 Lard, fatback, bacon fat
0 Stick margarine 0 Low-tat margarine 0 Crisco
0 Soft tub margarine 0 Corn oil, vegetable oil
0 Butter 0 Olive oil or canola oil
PLEASE 00 NOT WRITE IN THIS 5551,
199148 =
Illock 'IC.:' 01998 I300S, P',000 ffilOi.7,l.' 15,10S
S
S
S
S
S
S
S
S
S
S
S
101
During the past.year, have you taken any vitamins or minerals regularly, at least once a month?
0 No, not regularly0 Yes, fairly regularly-a
hF YS WHAT DID YOU TAKE FAIRLY REGULARLY?
VITAMIN TYPE HOWOFTEN FORHOWMANYYEARS?
DAYSDAYSI DAYS I LESS
DIDN'Tper
ISKE IOKTh
par
WEEK
per
WEEK
EVERVI
DAY
THAN
1 YR
I
YEAS
2
YEARS
3-6
YEARS
5-9
YEARS
tO.
YEARS
Multipie Vitamins. Did you take...
I
Regular Once-A-Day, Centrum, or Thera type0 0000 000000
Stress-tabs or B-Complex type 0 0000 000000
Antioxidant combination type 0 0000 000000
Single Vitamins (not part of multiple vitamins)
I
Vitamin A (not beta-carotene) 0 0000 000000
Beta-carotene 0 00
J00 000000
VitaminC 000'Q00000001
VitaminE 0 0OJO0 000000J
Folio acid, folate 0-oo-o0 000000 I
Calcium, alone or combined with something else0 0000 000000
Zinc, alone or combined with someth(ng else0 0000 000000
iron 0 010100 0000001
Selenium 0, 0L°1Po 00L00j
ii you took Once-a-day, Centrum or Thera-type 0 contain minerals,0 do not contain0 don't
multiple vitamins, did you usually take types that iron, zinc, etc. minerals know
It you took vitamin C or vitamin E:
How many milligrams of vitamin C did you usually take, on the days you took it?
0 100025005000750 0 1000 01500 02000 03000+0 Don't know
How many tUs of vitamin E did you usually take, on the days you took it?
0 100020003000400 0 6000800 0 1000 0 2000+0 Don't know
Did you take any of these suppiements at least once a month?
0 Ginkgo 0 Ginseng 0 St. John's Wort0 Kava Kava 0 Echinacea 0 Melatonin0 DHEA
0 Glucosamine/Chondroitin 0 Something else 0 Didn't take these
The next section is about your 11! eating habits in the past year or so. This includes all meais or
snacks, at home or in a restaurant or carry-out. There are two kinds of questions to answer for each food:
i-lOW OFTEN, on average, did you eat the food during the past year?
Please DO NOT SKIP any toods. Mark "Never" if you didn't eat it.
HOW MUCH did you usually eat of the food?
Somelimes we ask hownyyou eat, such as 1 egg, 2 eggs, elc., ON THE DAYSyouEAT IT.
Sometimes we ask "how much" as A, B, C or D. LOOK AT THE ENCLOSED PICTURES. For each
food, pick the picture (bowls or plates) that looks the most like the serving size you usually eal.
(If you don't have pictures: A1/4 cup, B=I/2 cup, C=1 cup, D=2 cups.)
Sometimes we made the "D" column a darker color. This is just to remind you to make sure you
really eat that large a serving.
EXAMPLE: This person drank apple iuice twice a week, and had one glass each time. Once a week he ate a "C" sized
serving ot rice (about 1 cup).
HOW OFTEN
Apple juice
Rice
!
NEVER
FEW
TIMES
per
YEAR
I
I ONCE
Iper
MON.
2-3
TIMES
per
MON.
ONCE
per
WEEK
I
ITWICE
per
I
WEEK
4
TIMES
per
WEEK
5-6
TIMES
per
WEEK
I
I
EVERY
I
DAY
HOW MUCH EACH TIME
SEC PORTION SIZE
PICTURESFOR A-B-C-O
0
C)
0
C)0
0
0
c;1.
C)
0
0
010
0 J_J0
:91a5se5
How much each limeJJB
I !oJJo
I 0 I aCo
C)
P/1GE2102
:'.. .. :
4e..OFT 'JYV en NEVERTiMES
Ier
OtE
pm
XlMS
jfp
ONCE
ter
TIME5
per
11ME
er
TIMES
for
EVEI
DAYHow many gIsses On the
ARMO MOWEI WEEK daysoudrnk?;H: How often do you drink the following beverages? How many
Tomato juice or V-8 juice 00 0 0 0 0 ° me ? ?
Real.i.00% orange JUt.Qe or 9rapefrult
. HoWmay
. glass juice-Including fresh, froert or bottled00 0 0 0 0 0 0 0 pach time0 0 ,.
I 2 .3 '4
When you drinl orange juice, how often do 0 Usually calcium-fortified 0 I don't know
you drink a calcium-fortified brand? 0 Sometimes calclum-fortilied0 I don't drink orange juice
0 Hardly evercalcium-fortified
00 0 '0 0 0 0 0 How many 0 0 0
Kool-Aid, Hi-C, or other How many ;'
drinks with added vitamin C 00 0 0 D 0 0 0 0 glasses0 0 0
00 0 0 0 0 0 0 0 0 0 0 encueze
Instant breakfast milkshakes like How many
Carnation, diet shakes like SlimFast,00 0 0 0 0 0 0 0 glasses or 0 0 0 0
or liquid supplemenl like Ensure
. cans I 2 3 4
Glàsses.Ofntilk(anykiftd) 00 0 01 0 0 0 0 0
Howmany0 0 0 =
When you drink glasses of milk, what kind do youuuai1ydrink? MARK ONLY ONE:
0 Whole milk0 Reduced-fat 2% milk0 Low-fat 1% milk0 Non-fat milk
0 Rice milk 0 Soy milk 0 I don't drink milk or soy milk
HOW OFTEN NEWS j 't HOW MUCH EACH liME
Regular soft drinks, or bottled 00 0 0 0 0 0 0 0
many0 0 0 0 drinks like Srtapple (f diet drinks) or
1 2 3.4 5. canses
How many
Beer or non-alcoholic beer 00 0 0 0 0 0 0 0 bottles or0 0o0
cans 1 2 3.4 5.
What kind? MARKONLYONE: 0 Regular beer0 Light beer0 Non-alcoholic beer 0 Idon't drink beer
Wine or wine coolers 00 0 0 0 0 0 0 0 How many 0 0 0 0
Liquorormixeddrinks 00 0 0 0 0 0 0 0loyrnanY0 0
Glasses of water, tap or bottled 00 0 0 0 0 0 0 0 I-low many
:
Coffee, regular or decaf 0 0 0 0 0 0 0 0 0HOWmany
:
Tea or iced tea(herb teas) 0 0 0 0 0 0
I :
What do you usually add to coffee?
MARK ONLY ONE: oCiemnoi halt&hail 0 Nondairy creamer.) MilkUNone ot these
What do you usually add to tea? 0 Creamorhalt & halt 0Nondairy creamer 0Milk0None of these
Do you usually add sugar (or honey) to collee? C No 0 Yes IF YES, how many teaspoons each cup?r))O)r'3C
t2y00usually add sugar (or honey) to tea? C No C) Yes IF YES,howmany teaspoons each cup? hnci
i-'$(E 3 - W -103
199148
PtEASE-DO NOT WRITE IN THIS ARSA'C
.
. : oc000010000IoouRouao
:
HOW MUdCH TiME HOW 9FTEN tintERIY4ER. E E
! : ....
Per+VERY DAY P1RES'FbRA-BD
. MONtHMONThWfEWEI!LW
How often do you eat each of the following fruits, justduring the 2-3 months when they are In season?
R ctannes, HOWmaRY
Cntaloupe,inséason .0Q.000 0.000Howmuch000
-Strawberries,inseason 00000 0000I-low mucho000
A B C 0
-Watermelon, in season 00000 0000 HOw much0000
-
kiWI00000 00
I00How much0000
How often do you eat the following foods aityear round?Estimate your average for the wholeyear.
:Bananas 000000000 ??
Applesorpears 0000000 0.HoWhranY00
Oranges or tangerines 000000000 0000
Grapefruit 000000000How much00Ô.o
trui apples:uce, fruit000000000 How much0000
HOW OFTEN I'vm HOW MUEAH?!ME Eggs, including egg biscuits or Egg 0 0 0 How many 0 0 0 00 0 McMuffins (Not egg substitutes)
eggs each time? ? ? '9
'Bacon 0000000.00 Howrnany 0000
including0 0 0 0 0 0 0 0 0How many0 0
waffles, French toast,0 0 0 0 0 0 0 0 0 °Y9 9 9 9 Breakfast bars, granola bars,0 0 0 0 0 0 0 0 0How many 0 0 0 0 Powerbars
t 2 3 4 Cooked cere&s ke oatmeal,0 0 0 0 0 0 0 0 0 Whichbowl0 0 0
h:fiberCea!ShkHBran,0 0 0 0 0 0 0 0 0Which bowl0 0 0
J
Which high-fiber cereal do you eat most often? MARKONLY ONE: 0 All Branor Bran Buds 0 Raisin Bran 0 Fiber One, Fruit-n-Fiber, elc.0Something else 0 I don't know 0 I don'l eat it
Just Right or 0 0 0 0 0 0 0 0 0Which bowl0 0 0
Q0 0 0 0tC) UWhich bowl0 0 0 Flakes, Cheerio
Milk or milk substitutes on cerealc o c 0 0 0 0 o0 How many0 0 0 0 oz. on cereal
,
Yogurt or frozen yogurt C)C) 0 0 C) 0 C)C)C) HOw muchC) 0 C) 0
A B C 0 Cheese sliced cheese or cheese - - - . - How many 0 C)C.)C' U'iC) 00 000 C) spread, including on sandwiches &ices
2 3 4
When you eat cheese, is it Ci Usually low-fat C)Sometimes low-fatC) Hardly ever low-fat 0 Don'tknow/don't eat
P,&i.,C104
PL$E-DQNTWRITEINTSAREA
199148000000*0000looJUUUQot
AFEV 24 2 HOW MUCH EATIME
HOW OFTEN NEVER SEE POi1N SEE
Y4RMONThMONTh twa PICTURES FOR AB.O-D
How often do you eat the following vegetables, Including fresh, frozen, canned or in stir-fry, at homeor
In a restaurant?
Broccoli '00O000OI00fo(olo,10
Carrots, or mixed vegetables or I-tow b stews containing carrots much A B
Corn ooooooooo
How0000
Green beans orgreen peas 000000000 ??9
Spinach 0000000000000
Mustard greens, turnIp greens, collards000000000 0000
French files, fried potatoes or hash browns.o00000000 0000
White potatoes not fried,mci.boiled,o00000o00
How0000 baked, mashed&potato salad much A B
Sweet potatoes, yams (Not in pie) o00000000 0000
Coleslaw,cabbage 000000000 0000
Greensalad 000000000How
much0
A0
B0
c0
Raw tomatoes, including in salad o00000000
How0000 much 1/4 i 2
How Saladdressing 000000000many0000.
Tbsp. 1 , 2 3 4
Is your salad dressing0 Usually low-fat0Sometimestow-fal0 Hardlyever low-fat0Don'tknow/don'tuse
HOW OFTEN HOW MUCH EACH TIME
Any other vegetable, like okra. 000000000How0000 squash, cooked green peppers much A B C
Refried beans or bean burritos 000000000Ho
Chili with beans (with or without meat> 000000000How0000
000000000muth? ntoanyotherdiledbeans
Vegelable stew 000000000 000-
Vegetable soup, vegetable be:t, 000000000wc 00 :
Split pea, bean or lentil soup o00000000 000 -
Any other soup, like chicken noodle,0000 0000Which 000 chowder, mushroom, instant soups Bowl B C
Spaghetti, lasagna or other pasta -
withtornalesauce 000000000r
Cheese dishes WJJhQUI tomato 0C)C)0 ()00How0000
isauce, like macaroni and cheese much A B
Pizza, including carry-out 0C)CC0C)CC)0 0000 esi23
frf.(./J- - -----
-
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HOWOFrEN PIcPD
Noodles, macaroni, pasta salad 00000 0000 0000
Tefu, bash curd 00Q00 0000 00OO
00000 0000Hny00 0 Ônburgers
Chinese food, Thai orotherAsian00000 00o0 How0000
food, not counted above much A B C b
Snacks like potato chips, corn How chips, popcorn (not pretzels) 00000 0000 much
Are these snacks 0 Usually low-fat0SometimesLow-fat.0Hardly everioWfa.0Don't know/don'teat
HQWOFTEN
. B HoWMuqçP
Peanuts, other nuts or seeds 0 0 0 0 0 0 0 0 0 0 0 0 0
Crackers 0000000000000
Doughnuts, Danish pastry 0 0 0 0 0 0 0 0 0 0 0 0
Cake, sweet rolls, coffee cake0 0 0 0 0 0 0 0 0 0 0 Q
Are they oUsually low-fat0 Sometimes low-fat 0 Hardly ever low-fat 0 Don't know/don't eat
Cookies
Are your cookies0 Usually low-fat0 Sometimes low-fat 0 Hardly ever low-tat 0 I don't know/don't eat
lcecream,icemilk,icecreambarsoI000J000IoIoI
Is your ice cream 0 Usually low-fat0 Somelimes low-fat 0 Hardly ever low-Cal 0 I don't know/don't eat
How many Pumpkin pie, Sweet potato pie0 0 0 0 0 0 0 0 0 0 0
Any other pie or cobbler 0 0 0 0 0 0 0 0 0
How many0
Chocolate candy, candy bars 0 0 0 0 0 0 0 0 0Ho5rany
mn,
Other candy, not chocolate j<e0 0 0 0 0 0 0
How many 0
____
-
107
Biscuits or muffins 000000000 0000
labnbger buns, Eeiglith q How many
Dcibread like rye or whole 000000000 SliCeseac000,0 wheat, including in sandwiches
time I 2 3 4
WBe bread or toast, including o Q000000 many0000
French, Italian, or in sandwiches .0
Sims each 2 3
Corn bread, corn muffins 000000000How many0000
Tortillas 000000.000 0000
Rice, or dishes made with rice 000000000How much0000
Margarine (not butter) on bread or0 0000000
or000000000 onpoitoesoregebies,Edc. ??
Gravy 00000000Cmarsp0000
Peanut butter 000000000mai0sp?
Jelly, jam, or syrup 000000000marsp
Mayonnaise, sandwich spreads000000000mai0sp
Catsup, salsa or chile peppers CC0000000mar°,sp00oo
Mustard, soy sauce, steak sauce,000000000
How0000 barbecue sauce, other sauces many bsp
1 2 3 4
Old you use the pictures to choose your serving size ore this form? 0 Yes 0 No0 I didn't have any pictures.
Would you say your health is0 Excellent0 Very good 0 Good0 Fair0 Poor
How many times have you gone on a diet? 0 Never0 1-20 3-50 6-8 0 9 or more
Did you ever drink more beer, wine or liquor than you do now? 0 Yes 0 No
How many hours do you watch television or video, per day or per week on average?
0 None 0 1-6 hours/week 0 1 hour/day 0 2 hours/day03 hours/day0 4+ hours/day
Do you smoke cigarettes now? 0 No 0 Yes
IF YES, On the average about how many cigarettes a day do you smoke now?
0 1-50 6-140 15-24025-34 035 or more
What language do you usually speak at home or with friends?
oEnglish 0 Sparnsli C) Something else C English&something else equally
What is your ethnic group? (MARK ONE OR MORE)
0 Hispanic or Lalino 0 Black or Atrican American C Ameiican Indianor Alaska Native
0 White, not Hispanic C) Asian 0 Native Hawaiianor Other Pacilic slander
PLEASE DO NOT WRiTE IN THIS AREA
199148
F',4GEO Ntl4cIkI.NL:K:S.'flO;I.E 4FOOD QUESTIONNAp
Serving SizeChoices
Keep this in front ofyou while you are filling outThe Food Questionnaire.You may use elthrthe plates orthe bowls to help you choose your serving size.
Choose A, B, C or D: A= 1/4 Cup of FoodB= l/2CUpOf Food C=1 CUPOfFOOd D=2CupsofFood
© Block Dietary Data Systems,Berkeley, CA (510) 704-8514.htfp://wwJ,nutrifionquest corn